Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyBiologicalProcess	response to abiotic stimulus	ICOSLG FLT1 NR2E3 RIPOR2 ERCC5 USP28 PCARE ITGAM WNK1 DNAJC2 HOXA1 WDR47 TGFBR3 PIEZO2 SCAP ARSA NF1 PTPRC NFATC3 KCNJ11 POLI TANC1 LRRN4 TACC3 ENG KDM6A PRL TP53BP1	1.42e-05	1361	177	28	GO:0009628
GeneOntologyBiologicalProcess	cell cycle process	RIPOR2 RBL2 USP28 KIZ CUL9 TEX15 WNK1 FOXJ3 BIRC6 STAMBP WAC LLGL1 PTPRC ATRIP ALMS1 MBTPS2 USP51 MARF1 MLF1 ANKRD17 ZFYVE26 TNKS MTCL1 TACC3 GOLGA8A PHIP TP53BP1 PCNT NPAT	1.48e-05	1441	177	29	GO:0022402
Domain	FN3	KALRN PTPRC PTPRO IGSF9 EGFLAM LRRN4 IL2RB HCFC1 EPHA7	6.63e-05	185	176	9	SM00060
Domain	DUF3480	ZFYVE16 ZFYVE9	8.83e-05	2	176	2	PF11979
Domain	DUF3480	ZFYVE16 ZFYVE9	8.83e-05	2	176	2	IPR022557
Domain	Znf_FYVE_endofin	ZFYVE16 ZFYVE9	8.83e-05	2	176	2	IPR017165
Domain	-	TRIM25 ZFYVE16 RNF19A JADE2 ZNF521 DIDO1 RNF157 ZFYVE9 USP51 PHF3 RNFT1 ZFYVE26 KAT6B RNF182	9.41e-05	449	176	14	3.30.40.10
Domain	FN3	KALRN PTPRC PTPRO IGSF9 EGFLAM LRRN4 IL2RB HCFC1 EPHA7	1.16e-04	199	176	9	PS50853
Domain	Znf_RING/FYVE/PHD	TRIM25 ZFYVE16 RNF19A JADE2 ZNF521 DIDO1 RNF157 ZFYVE9 USP51 PHF3 RNFT1 ZFYVE26 KAT6B RNF182	1.19e-04	459	176	14	IPR013083
Domain	Ig-like_fold	ICOSLG FLT1 KALRN EBF3 SIRPG FCRL3 PTPRC NFATC3 PTPRO ALPK3 IGSF9 EGFLAM LRRN4 LY9 IL2RB HCFC1 PLXNA2 EPHA7	1.26e-04	706	176	18	IPR013783
Domain	FN3_dom	KALRN PTPRC PTPRO IGSF9 EGFLAM LRRN4 IL2RB HCFC1 EPHA7	1.68e-04	209	176	9	IPR003961
Domain	-	FLT1 KALRN EBF3 SIRPG FCRL3 PTPRC NFATC3 PTPRO ALPK3 IGSF9 EGFLAM LRRN4 LY9 IL2RB HCFC1 PLXNA2 EPHA7	1.83e-04	663	176	17	2.60.40.10
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	NYAP2 CTTNBP2 UBAP2 ANK2 KALRN EBF3 USP28 RGPD1 DIDO1 WDR47 SIRPG GDA NF1 NFATC3 KCNJ16 ANKRD17 TNKS LIMCH1 MTCL1 QSER1 TACC3 GOLGA8A ARHGAP21 TP53BP1 PCNT	4.96e-11	963	182	25	28671696
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: II. The complete nucleotide sequences of 400 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	RIPOR2 ZFYVE16 ATG13 CUL9 FAM91A1 RNF157 RUSC2 WDR47 PHF3 TCF25 LIMCH1 MTCL1 MCF2L ARHGAP21 PLXNA2 PCNT	5.54e-10	407	182	16	12693553
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	DENND4A RAPGEF6 HIVEP1 UBAP2 CARMIL2 ATG13 KCTD8 ITPRID2 WNK1 SPECC1 GLCCI1 RUSC2 NF1 ALMS1 NFATC3 PHF3 PLEKHA3 ANKRD17 TANC1 LIMCH1 MTCL1 ARHGAP21	1.05e-09	861	182	22	36931259
Pubmed	Prediction of the coding sequences of unidentified human genes. VII. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro.	RIPOR2 ZFYVE16 DIDO1 WNK1 RUSC2 ALMS1 ZFYVE26 MCF2L KAT6B	4.32e-09	104	182	9	9205841
Pubmed	Proximity-dependent biotin identification (BioID) reveals a dynamic LSD1-CoREST interactome during embryonic stem cell differentiation.	RAPGEF6 HIVEP1 ZFYVE16 RGPD1 BIRC6 JMJD1C GREB1L GTF3C1 ALMS1 ANKRD17 FOXP1 TACC3 ARHGAP21 PCNT NPAT	6.68e-09	418	182	15	34709266
Pubmed	Large-scale characterization of HeLa cell nuclear phosphoproteins.	RAPGEF6 HIVEP1 GCFC2 ERCC5 FAM91A1 DIDO1 ITPRID2 NF1 PTPRC GTF3C1 PHF3 TMPO ANKRD17 LIMCH1 TACC3 KAT6B KDM6A MED13 TP53BP1	2.94e-08	774	182	19	15302935
Pubmed	A human skeletal muscle interactome centered on proteins involved in muscular dystrophies: LGMD interactome.	DENND4A HIVEP1 CTTNBP2 ANK2 KALRN DTNA TNFRSF6B WNK1 BIRC6 JMJD1C ALMS1 MLF1 TNKS ARHGAP21 MED13	6.53e-08	497	182	15	23414517
Pubmed	Identifications of novel host cell factors that interact with the receptor-binding domain of the SARS-CoV-2 spike protein.	SECISBP2L DENND4A RAPGEF6 FAM91A1 DIDO1 JMJD1C RUSC2 SMYD4 LLGL1 GTF3C1 MARF1 TCF25 ANKRD17 TANC1 QSER1 HCFC1 ARHGAP21	6.65e-08	650	182	17	38777146
Pubmed	Transcriptome analysis of mouse stem cells and early embryos.	TMPPE RNF19A ZSCAN5A RPP30 WNK1 BIRC6 GLCCI1 WAC SMYD4 ZSCAN5C TMPO PRL EPHA7	7.19e-08	363	182	13	14691545
Pubmed	Proximity-dependent Mapping of the Androgen Receptor Identifies Kruppel-like Factor 4 as a Functional Partner.	HIVEP1 USP28 JMJD1C WAC CCNT1 PHF3 FOXP1 QSER1 KDM6A HCFC1 MED13	1.94e-07	268	182	11	33640491
Pubmed	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.	AKIRIN1 JADE2 DTNA ATG13 KIZ GRIK1 ZNF385B FOXJ3 JMJD1C TASOR2 PLEKHG4B ARHGAP6 GTF3C1 TBC1D22A OSBPL5 ANKRD17 IGSF9 FOXP1 TANC1 LIMCH1 QSER1 MCF2L KAT6B KDM6A PCNT	2.87e-07	1489	182	25	28611215
Pubmed	Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability.	KRT1 HIVEP1 DTNA USP28 CUL9 AASDH ITPRID2 WNK1 ALMS1 NFATC3 PRDX3 TANC1 FAM135A TP53BP1 PCNT	5.57e-07	588	182	15	38580884
Pubmed	Construction of a multi-functional cDNA library specific for mouse pancreatic islets and its application to microarray.	FLT1 ANK2 JADE2 CUL9 FOXJ3 JMJD1C WAC TTLL7 FICD MTCL1 KAT6B ARHGAP21	6.82e-07	371	182	12	15747579
Pubmed	Endofin is required for HD-PTP and ESCRT-0 interdependent endosomal sorting of ubiquitinated transmembrane cargoes.	ZFYVE16 WNK1 BIRC6 ZFYVE9 ALMS1 PRDX3	7.49e-07	60	182	6	34761192
Pubmed	A genome-wide screen to identify transcription factors expressed in pelvic Ganglia of the lower urinary tract.	NR2E3 HIVEP1 EBF3 JADE2 ZNF521 DIDO1 FOXJ3 BIRC6 HOXA1 GTF3C1 SPDEF PAX3 TACC3 KAT6B PHIP PLXNA2	1.15e-06	709	182	16	22988430
Pubmed	Protein interactome reveals converging molecular pathways among autism disorders.	HIVEP1 OAZ1 ITPRID2 SPECC1 TASOR2 RUSC2 HOXA1 NF1 TCF25 TMPO IGSF9 TACC3 USPL1 ADAMTSL4	1.70e-06	560	182	14	21653829
Pubmed	An antibody-based proximity labeling map reveals mechanisms of SARS-CoV-2 inhibition of antiviral immunity.	PHLDB3 GCFC2 UBAP2 ATP7B ZFYVE16 WNK1 BIRC6 JMJD1C SCAP ALMS1 TBC1D22A PHF3 MLF1 TANC1 QSER1 HCFC1	1.77e-06	733	182	16	34672954
Pubmed	Human transcription factor protein interaction networks.	HIVEP1 UBAP2 DET1 DTNA RGPD1 ZNF521 CUL9 DIDO1 PROSER1 JMJD1C TFDP2 GTF3C1 ALMS1 NFATC3 PRDX3 MARF1 ANKRD17 FOXP1 QSER1 KDM6A HCFC1 TP53BP1 NPAT	1.83e-06	1429	182	23	35140242
Pubmed	The Functional Proximal Proteome of Oncogenic Ras Includes mTORC2.	COL16A1 CARMIL2 ANK2 DTNA SPECC1 PIEZO2 NF1 LLGL1 PCDH11X TANC1 FAM135A ARHGAP21 PLXNA2 EPHA7	2.05e-06	569	182	14	30639242
Pubmed	Menin and Menin-Associated Proteins Coregulate Cancer Energy Metabolism.	RPP30 DIDO1 JMJD1C WAC CCNT1 GTF3C1 WDR75 TCF25 KAT6B HCFC1 TP53BP1	2.06e-06	341	182	11	32971831
Pubmed	Proteome-scale mapping of binding sites in the unstructured regions of the human proteome.	RAPGEF6 UBAP2 TRIM25 AKIRIN1 ITPRID2 WNK1 FOXJ3 TASOR2 PLEKHG4B ARHGAP6 TNKS PCNT	3.15e-06	430	182	12	35044719
Pubmed	An atlas of combinatorial transcriptional regulation in mouse and man.	NR2E3 DENND4A GCFC2 TRIM25 EBF3 JADE2 RBL2 TFDP2 HOXA1 ANKRD33 GTF3C1 NFATC3 ZNF398 SPDEF FOXP1 PAX3 HCFC1	4.09e-06	877	182	17	20211142
Pubmed	Construction of long-transcript enriched cDNA libraries from submicrogram amounts of total RNAs by a universal PCR amplification method.	TRPM6 RIPOR2 RAPGEF6 ERCC5 ATG13 FAM91A1 DIDO1 WNK1 FOXJ3 SCAP PTPRC WDR75 ANKRD17 QSER1 FAM135A ARHGAP21 TP53BP1 PCNT NPAT	4.64e-06	1084	182	19	11544199
Pubmed	The ubiquitin ligase Uhrf2 is a master regulator of cholesterol biosynthesis and is essential for liver regeneration.	RGPD1 TASOR2 PHF3 TMPO HCFC1 PHIP	6.28e-06	86	182	6	37253089
Pubmed	Comparative interactome analysis of α-arrestin families in human and Drosophila.	TRIM25 DTNA CUL9 FAM91A1 CCNT1 NF1 LLGL1 GTF3C1 WDR75 HCFC1	6.60e-06	313	182	10	38270169
Pubmed	SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway.	RAPGEF6 UBAP2 DIDO1 JMJD1C GTF3C1 ALMS1 PHF3 TMPO QSER1 TACC3 KDM6A HCFC1 TP53BP1	7.23e-06	549	182	13	38280479
Pubmed	Cellular phenotypes and spatio-temporal patterns of lymphatic vessel development in embryonic mouse hearts.	ITGAM PTPRC CD68	7.74e-06	8	182	3	22753134
Pubmed	The PHLPP1 N-Terminal Extension Is a Mitotic Cdk1 Substrate and Controls an Interactome Switch.	RAPGEF6 UBAP2 FAM91A1 DIDO1 JMJD1C ANKRD17 TANC1 LIMCH1 HCFC1	9.01e-06	256	182	9	33397691
Pubmed	N-Terminal Acetyltransferase Naa40p Whereabouts Put into N-Terminal Proteoform Perspective.	RAPGEF6 UBAP2 TRIM25 ANK2 ZFYVE16 USP28 DIDO1 WNK1 WAC CCNT1 ALMS1 TMPO ANKRD17 HCFC1 ARHGAP21 TP53BP1 PCNT	9.30e-06	934	182	17	33916271
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: IV. The complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	SECISBP2L CTTNBP2 WNK1 BIRC6 JMJD1C WAC SMYD4 GDA KRBA1 SCAP ALMS1 FAM135A	1.25e-05	493	182	12	15368895
Pubmed	Proteomic analyses reveal distinct chromatin-associated and soluble transcription factor complexes.	EBF3 RBL2 USP28 CUL9 FOXJ3 JMJD1C KBTBD7 TTLL7 WDR47 GTF3C1 ANKRD17 FOXP1 PAX3 QSER1 HCFC1 TP53BP1	1.26e-05	857	182	16	25609649
Pubmed	Unbiased Identification of trans Regulators of ADAR and A-to-I RNA Editing.	TRIM25 ANK2 RGPD1 DIDO1 TASOR2 CCNT1 TMPO HCFC1 TP53BP1	1.42e-05	271	182	9	32433965
Pubmed	Prediction of the coding sequences of unidentified human genes. XVI. The complete sequences of 150 new cDNA clones from brain which code for large proteins in vitro.	JMJD1C PCDH11X ALPK3 ZNF398 IGSF9 FAM135A ARHGAP21	1.71e-05	153	182	7	10718198
Pubmed	Proximity labeling of endogenous RICTOR identifies mTOR complex 2 regulation by ADP ribosylation factor ARF1.	GCFC2 UBAP2 RGPD1 CCNT1 GTF3C1 WDR75 TMPO ANKRD17	1.91e-05	215	182	8	35973513
Pubmed	BioID reveals an ATG9A interaction with ATG13-ATG101 in the degradation of p62/SQSTM1-ubiquitin clusters.	DENND4A ATP7B ZFYVE16 ATG13 FAM91A1 ZFYVE9 ATRIP TMPO FAM135A	2.11e-05	285	182	9	34369648
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	PHLDB3 RAPGEF6 LPAR5 KALRN CUL9 WNK1 BIRC6 SCAP KCNJ11 OSBPL5 ZNF398 ZFYVE26 TANC1 MCF2L HCFC1 ARHGAP21 MED13 PCNT	2.22e-05	1105	182	18	35748872
Pubmed	Interleukin-11 signaling is required for the differentiation of natural killer cells at the maternal-fetal interface.	PTPRC ENG PRL	2.26e-05	11	182	3	15499555
Pubmed	Gradual centriole maturation associates with the mitotic surveillance pathway in mouse development.	USP28 TP53BP1 PCNT	2.26e-05	11	182	3	33410253
Pubmed	Resolution of cell fate decisions revealed by single-cell gene expression analysis from zygote to blastocyst.	NR2E3 HIVEP1 EBF3 ZSCAN5A DIDO1 FOXJ3 TFDP2 KRBA1 ZSCAN5C ZNF398 SPDEF FOXP1 KAT6B KDM6A PLXNA2	2.54e-05	808	182	15	20412781
Pubmed	Characterisation of syncytiotrophoblast vesicles in normal pregnancy and pre-eclampsia: expression of Flt-1 and endoglin.	FLT1 ENG	2.72e-05	2	182	2	23437230
Pubmed	Endoglin is expressed on human chondrocytes and forms a heteromeric complex with betaglycan in a ligand and type II TGFbeta receptor independent manner.	TGFBR3 ENG	2.72e-05	2	182	2	12568406
Pubmed	Maternal imbalance between pro-angiogenic and anti-angiogenic factors in HIV-infected women with pre-eclampsia.	FLT1 ENG	2.72e-05	2	182	2	24217170
Pubmed	Unexplained fetal death is associated with increased concentrations of anti-angiogenic factors in amniotic fluid.	FLT1 ENG	2.72e-05	2	182	2	20199197
Pubmed	Early anti-angiogenic proteins expression in amniotic fluid of twin fetuses.	FLT1 ENG	2.72e-05	2	182	2	21962138
Pubmed	Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated preeclampsia.	FLT1 ENG	2.72e-05	2	182	2	23806447
Pubmed	Differentiation of human pluripotent stem cells into neurons or cortical organoids requires transcriptional co-regulation by UTX and 53BP1.	KDM6A TP53BP1	2.72e-05	2	182	2	30718900
Pubmed	Inhibition of transforming growth factor-beta1-induced signaling and epithelial-to-mesenchymal transition by the Smad-binding peptide aptamer Trx-SARA.	ZFYVE16 ZFYVE9	2.72e-05	2	182	2	16775010
Pubmed	YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia.	FLT1 ENG	2.72e-05	2	182	2	26159901
Pubmed	Correlations among antiangiogenic factors and trace elements in hypertensive disorders of pregnancy.	FLT1 ENG	2.72e-05	2	182	2	25053574
Pubmed	First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia.	FLT1 ENG	2.72e-05	2	182	2	18771978
Pubmed	Increased plasma soluble fms-like tyrosine kinase 1 and endoglin levels in pregnancies complicated with preeclampsia.	FLT1 ENG	2.72e-05	2	182	2	19350449
Pubmed	Control of cell proliferation by memories of mitosis.	USP28 TP53BP1	2.72e-05	2	182	2	38547292
Pubmed	PAX3 promotes tumor progression via CD105 signaling.	PAX3 ENG	2.72e-05	2	182	2	23274166
Pubmed	Uteroplacental arterio-venous difference in soluble VEGFR-1 (sFlt-1), but not in soluble endoglin concentrations in preeclampsia.	FLT1 ENG	2.72e-05	2	182	2	22264588
Pubmed	Expression of monocyte and lymphocyte adhesion molecules is increased in isolated coronary artery ectasia.	ITGAM PTPRC	2.72e-05	2	182	2	17172930
Pubmed	Native Piezo2 Interactomics Identifies Pericentrin as a Novel Regulator of Piezo2 in Somatosensory Neurons.	PIEZO2 PCNT	2.72e-05	2	182	2	27345391
Pubmed	Soluble endoglin (sEng) joins the soluble fms-like tyrosine kinase (sFlt) receptor as a pre-eclampsia molecule.	FLT1 ENG	2.72e-05	2	182	2	16870672
Pubmed	Whole-genome microarray and targeted analysis of angiogenesis-regulating gene expression (ENG, FLT1, VEGF, PlGF) in placentas from pre-eclamptic and small-for-gestational-age pregnancies.	FLT1 ENG	2.72e-05	2	182	2	18330824
Pubmed	Myocardial performance index in hypertensive disorders of pregnancy: The relationship between blood pressures and angiogenic factors.	FLT1 ENG	2.72e-05	2	182	2	28609171
Pubmed	Increased serum levels of anti-angiogenic factors soluble fms-like tyrosine kinase and soluble endoglin in sickle cell disease.	FLT1 ENG	2.72e-05	2	182	2	19039203
Pubmed	Rhinovirus colocalizes with CD68- and CD11b-positive macrophages following experimental infection in humans.	ITGAM CD68	2.72e-05	2	182	2	23727038
Pubmed	Soluble endoglin is an accurate predictor and a pathogenic molecule in pre-eclampsia.	FLT1 ENG	2.72e-05	2	182	2	17210583
Pubmed	Paladin (X99384) is expressed in the vasculature and shifts from endothelial to vascular smooth muscle cells during mouse development.	ITGAM PTPRC CD68	3.88e-05	13	182	3	22354871
Pubmed	Quantitative dissection and stoichiometry determination of the human SET1/MLL histone methyltransferase complexes.	JADE2 USP28 QSER1 KDM6A HCFC1 TP53BP1	4.02e-05	119	182	6	23508102
Pubmed	Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription.	CUL9 DIDO1 BIRC6 TASOR2 NF1 GTF3C1 WDR75 PHF3 ANKRD17 HCFC1 PHIP TP53BP1 PCNT	4.41e-05	653	182	13	22586326
Pubmed	Hdac4 Interactions in Huntington's Disease Viewed Through the Prism of Multiomics.	KALRN RPP30 ZNF385B SPRED3 DNAJC2 NF1 TNKS LIMCH1 MCF2L PHIP TP53BP1	4.53e-05	475	182	11	31040226
Pubmed	E-cadherin interactome complexity and robustness resolved by quantitative proteomics.	UBAP2 TRIM25 ZFYVE16 FAM91A1 ITPRID2 SPECC1 LLGL1 TMPO TANC1 LIMCH1 HCFC1 ARHGAP21	4.71e-05	565	182	12	25468996
Pubmed	Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.	ANK2 KALRN JADE2 RBL2 USP28 ZNF521 CUL9 GRIK1 OAZ1 SPECC1 STAMBP WAC WDR47 TNKS USPL1 KDM6A ARHGAP21 MED13 PCNT	4.85e-05	1285	182	19	35914814
Pubmed	In-Depth In Vivo Crosslinking in Minutes by a Compact, Membrane-Permeable, and Alkynyl-Enrichable Crosslinker.	KRT1 DENND4A ERCC5 ANK2 DTNA DACT2 RGPD1 TASOR2 GTF3C1 WDR75 MARF1 TMPO SPDEF LIMCH1 MCF2L USPL1 ARHGAP21 MED13 PLXNA2 PCNT	7.35e-05	1442	182	20	35575683
Pubmed	PRISMA and BioID disclose a motifs-based interactome of the intrinsically disordered transcription factor C/EBPα.	HIVEP1 TRIM25 EBF3 RPP30 DIDO1 AASDH FOXJ3 JMJD1C WAC CCNT1 GTF3C1 TMPO FOXP1 QSER1 KDM6A HCFC1 TP53BP1	7.48e-05	1103	182	17	34189442
Pubmed	Transcriptome characterization elucidates signaling networks that control human ES cell growth and differentiation.	RIPOR2 CTTNBP2 ANK2 FAM91A1 DIDO1 SPECC1 HERC2P3 TASOR2 WAC GREB1L BNC1 SMYD4 PIEZO2 SCAP ARSA NF1 MARF1 MED13	7.54e-05	1215	182	18	15146197
Pubmed	A probability-based approach for high-throughput protein phosphorylation analysis and site localization.	KALRN DIDO1 WNK1 GLCCI1 WAC GTF3C1 PHF3 MTCL1 TACC3 HCFC1 TP53BP1	7.55e-05	503	182	11	16964243
Pubmed	Circulating Angiogenic Factors and the Risk of Preeclampsia in Systemic Lupus Erythematosus Pregnancies.	FLT1 ENG	8.14e-05	3	182	2	25979720
Pubmed	Maternal circulating angiogenic factors in twin and singleton pregnancies.	FLT1 ENG	8.14e-05	3	182	2	25434840
Pubmed	Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies.	FLT1 ENG	8.14e-05	3	182	2	20948996
Pubmed	Integrin alphaMbeta2 clustering triggers phosphorylation and activation of protein kinase C delta that regulates transcription factor Foxp1 expression in monocytes.	ITGAM FOXP1	8.14e-05	3	182	2	20190138
Pubmed	A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate.	FLT1 ENG	8.14e-05	3	182	2	18175241
Pubmed	CD11b+ bone marrow-derived monocytes are the major leukocyte subset responsible for retinal capillary leukostasis in experimental diabetes in mouse and express high levels of CCR5 in the circulation.	ITGAM PTPRC	8.14e-05	3	182	2	22677420
Pubmed	Altered homeostasis and development of regulatory T cell subsets represent an IL-2R-dependent risk for diabetes in NOD mice.	PTPRC IL2RB	8.14e-05	3	182	2	29259102
Pubmed	Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study.	ITGAM PTPRC	8.14e-05	3	182	2	19546439
Pubmed	Mice expressing the variant rs1143679 allele of ITGAM (CD11b) show impaired DC-mediated T cell proliferation.	ITGAM PTPRC	8.14e-05	3	182	2	31673770
Pubmed	Maternal, gestational and neonatal characteristics and maternal angiogenic factors in normotensive pregnancies.	FLT1 ENG	8.14e-05	3	182	2	19135290
Pubmed	The dimeric deubiquitinase USP28 integrates 53BP1 and MYC functions to limit DNA damage.	USP28 TP53BP1	8.14e-05	3	182	2	38227944
Pubmed	Novel circulating placental markers prokineticin-1, soluble fms-like tyrosine kinase-1, soluble endoglin and placental growth factor and association with late miscarriage.	FLT1 ENG	8.14e-05	3	182	2	27664209
Pubmed	Three-gene prognostic biomarkers for seminoma identified by weighted gene co-expression network analysis.	ITGAM CD68	8.14e-05	3	182	2	33104706
Pubmed	Circulating angiogenic and antiangiogenic factors in women with eclampsia.	FLT1 ENG	8.14e-05	3	182	2	21062661
Pubmed	Drosophila Pgc protein inhibits P-TEFb recruitment to chromatin in primordial germ cells.	PGC CCNT1	8.14e-05	3	182	2	18200011
Pubmed	Serum sFlt1:PlGF ratio, PlGF, and soluble endoglin levels in gestational proteinuria.	FLT1 ENG	8.14e-05	3	182	2	19165674
Pubmed	Angiogenic Factors in Preeclampsia: From Diagnosis to Therapy.	FLT1 ENG	8.14e-05	3	182	2	27067718
Pubmed	The tumor suppressor Rb and its related Rbl2 genes are regulated by Utx histone demethylase.	RBL2 KDM6A	8.14e-05	3	182	2	20650264
Pubmed	Neurofibromin knockdown in glioma cell lines is associated with changes in cytokine and chemokine secretion in vitro.	NF1 ENG	8.14e-05	3	182	2	29643433
Pubmed	Dysregulation of complement system in HELLP syndrome.	FLT1 ENG	8.14e-05	3	182	2	34697959
Pubmed	Independent risk factors for a small placenta and a small-for-gestational-age infant at 35-41 weeks of gestation: An association with circulating angiogenesis-related factor levels at 19-31 weeks of gestation.	FLT1 ENG	8.14e-05	3	182	2	28613009
Pubmed	Mid-pregnancy levels of angiogenic markers as indicators of pathways to preterm delivery.	FLT1 ENG	8.14e-05	3	182	2	21939291
Pubmed	Centrosome defects cause microcephaly by activating the 53BP1-USP28-TP53 mitotic surveillance pathway.	USP28 TP53BP1	8.14e-05	3	182	2	33226141
Pubmed	53BP1 Integrates DNA Repair and p53-Dependent Cell Fate Decisions via Distinct Mechanisms.	USP28 TP53BP1	8.14e-05	3	182	2	27546791
Pubmed	Dual role of K ATP channel C-terminal motif in membrane targeting and metabolic regulation.	ANK2 KCNJ11	8.14e-05	3	182	2	19805355
Pubmed	ALK1 regulates the internalization of endoglin and the type III TGF-β receptor.	TGFBR3 ENG	8.14e-05	3	182	2	33566682
Pubmed	Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies.	FLT1 ENG	8.14e-05	3	182	2	17956952
Pubmed	Maternal circulating levels of activin A, inhibin A, sFlt-1 and endoglin at parturition in normal pregnancy and pre-eclampsia.	FLT1 ENG	8.14e-05	3	182	2	19412349
Interaction	WWTR1 interactions	RAPGEF6 UBAP2 TRIM25 DIDO1 JMJD1C GTF3C1 ALMS1 PHF3 PAX3 QSER1 TACC3 ENG KDM6A HCFC1 TP53BP1	5.42e-06	422	178	15	int:WWTR1
Interaction	GOLGA1 interactions	RAPGEF6 TRIM25 ATP7B RGPD1 FAM91A1 BIRC6 SCAP ALMS1 TANC1 PCNT	5.44e-06	183	178	10	int:GOLGA1
Interaction	ZYX interactions	SECISBP2L TRIM25 ANK2 WNK1 PLEKHG4B ALMS1 C17orf78 TANC1 LIMCH1 TACC3 FAM135A ARHGAP21 PCNT	7.63e-06	329	178	13	int:ZYX
Interaction	TAFA4 interactions	ITPRID2 TGFBR3 MOXD1 M6PR PLXNA2 TCTN2	8.83e-06	55	178	6	int:TAFA4
GeneFamily	Fibronectin type III domain containing	KALRN PTPRC PTPRO IGSF9 EGFLAM LRRN4 EPHA7	9.11e-05	160	119	7	555
GeneFamily	Zinc fingers FYVE-type\|Pleckstrin homology domain containing\|Rho guanine nucleotide exchange factors	ZFYVE16 ZFYVE9 ZFYVE26	1.09e-03	31	119	3	81
GeneFamily	ADAM metallopeptidase domain containing\|CD molecules	ICOSLG ITGAM SIRPG FCRL3 PTPRC CD68 LY9 ENG IL2RB	1.19e-03	394	119	9	471
GeneFamily	Pleckstrin homology domain containing\|Rho guanine nucleotide exchange factors\|C2 domain containing	PHLDB3 PLEKHG4B PLEKHA3 OSBPL5 MCF2L ARHGAP21	2.43e-03	206	119	6	682
GeneFamily	PHD finger proteins	JADE2 DIDO1 PHF3 KAT6B	2.95e-03	90	119	4	88
GeneFamily	Potassium voltage-gated channel subfamily J	KCNJ11 KCNJ16	4.85e-03	16	119	2	276
GeneFamily	Ankyrin repeat domain containing	CTTNBP2 ANK2 ANKRD33 ANKRD17 TNKS TANC1	5.34e-03	242	119	6	403
GeneFamily	Ubiquitin specific peptidases	USP28 USP51 USPL1	5.98e-03	56	119	3	366
GeneFamily	Sulfatases	ARSA ARSF	6.14e-03	18	119	2	410
GeneFamily	CD molecules\|Membrane spanning 4-domains	MS4A18 MS4A3	6.14e-03	18	119	2	958
GeneFamily	Armadillo repeat containing\|Protein phosphatase 1 regulatory subunits	ZFYVE16 WNK1 PCDH11X MARF1 HCFC1	6.94e-03	181	119	5	694
Coexpression	CUI_TCF21_TARGETS_2_DN	SECISBP2L FLT1 RIPOR2 HIVEP1 CTTNBP2 AKIRIN1 ZFYVE16 DTNA ITPRID2 GLCCI1 TTLL7 SIRPG TGFBR3 PTPRC PTPRO OSBPL5 RNFT1 TCF25 TANC1 MTCL1 KDM6A FAM135A MED13	6.18e-08	888	182	23	MM1018
Coexpression	CUI_TCF21_TARGETS_2_DN	SECISBP2L FLT1 RIPOR2 HIVEP1 CTTNBP2 AKIRIN1 ZFYVE16 DTNA ITPRID2 GLCCI1 TTLL7 TGFBR3 PTPRC PTPRO OSBPL5 RNFT1 TCF25 TANC1 MTCL1 KDM6A FAM135A MED13	1.34e-07	854	182	22	M1533
Coexpression	NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_CORRELATED_WITH_HAI_28DY_RESPONSE_AT_3DY_NEGATIVE	SECISBP2L RAPGEF6 CFAP36 ATG13 DNAJC2 CCNT1 FOXP1 TNKS LY9 USPL1 KAT6B GOLGA8A KDM6A	1.69e-06	363	182	13	M41103
Coexpression	GSE3920_UNTREATED_VS_IFNA_TREATED_FIBROBLAST_UP	HIVEP1 WNK1 JMJD1C KBTBD7 RNF157 TASOR2 ANKRD17 TNKS USPL1	2.82e-06	168	182	9	M6704
Coexpression	GSE14415_INDUCED_TREG_VS_FOXP3_KO_INDUCED_TREG_UP	RAPGEF6 USP28 TGFBR3 KRBA1 WDR75 PRDX3 FOXP1 TANC1 QSER1	3.42e-06	172	182	9	M2951
Coexpression	AIZARANI_LIVER_C9_LSECS_1	FLT1 STAB2 JMJD1C MMRN1 TGFBR3 PIEZO2 TANC1 LIMCH1 MCF2L ENG PLXNA2	9.84e-06	304	182	11	M39113
Coexpression	BUSSLINGER_GASTRIC_IMMUNE_CELLS	DENND4A RIPOR2 RAPGEF6 AKIRIN1 SHFL RNF19A JADE2 RBL2 OAZ1 WNK1 FOXJ3 BIRC6 GLCCI1 JMJD1C WAC SIRPG TGFBR3 PTPRC NFATC3 PHF3 LY9 KAT6B IL2RB PHIP MED13 NPAT	1.42e-05	1492	182	26	M40023
Coexpression	ZHU_CMV_8_HR_DN	ERCC5 ZNF521 TGFBR3 ENG TP53BP1	2.51e-05	50	182	5	M9806
Coexpression	GSE14415_FOXP3_KO_NATURAL_TREG_VS_TCONV_DN	RAPGEF6 USP28 TGFBR3 WDR75 PRDX3 POLI FOXP1 TANC1	2.95e-05	173	182	8	M2953
Coexpression	DACOSTA_UV_RESPONSE_VIA_ERCC3_DN	SECISBP2L HIVEP1 ZFYVE16 FOXJ3 DNAJC2 TGFBR3 ZFYVE9 NFATC3 PHF3 ANKRD17 TNKS MTCL1 KAT6B PHIP MED13 TP53BP1 PCNT NPAT	3.12e-05	856	182	18	M4500
Coexpression	GSE27241_WT_VS_RORGT_KO_TH17_POLARIZED_CD4_TCELL_TREATED_WITH_DIGOXIN_UP	UBAP2 WNK1 BIRC6 NF1 GTF3C1 TNKS HCFC1 MED13	3.92e-05	180	182	8	M8239
Coexpression	GSE22886_NAIVE_CD8_TCELL_VS_MONOCYTE_UP	RAPGEF6 GCFC2 JADE2 TFDP2 SIRPG TGFBR3 LY9 IL2RB	7.94e-05	199	182	8	M4494
Coexpression	GSE39820_CTRL_VS_TGFBETA1_IL6_IL23A_CD4_TCELL_UP	AASDH JMJD1C TASOR2 CCNT1 PTPRC WDR75 KDM6A TP53BP1	7.94e-05	199	182	8	M5607
Coexpression	GSE24292_WT_VS_PPARG_KO_MACROPHAGE_DN	RAPGEF6 JADE2 WNK1 JMJD1C DNAJC2 PTPRO POLI LY9	8.22e-05	200	182	8	M8054
Coexpression	GSE25123_CTRL_VS_IL4_AND_ROSIGLITAZONE_STIM_MACROPHAGE_DN	MS4A18 GCFC2 KALRN MARF1 FOXP1 INSYN2B CCDC157 EPHA7	8.22e-05	200	182	8	M7909
Coexpression	NAKAYA_PBMC_FLUMIST_AGE_18_50YO_3DY_DN	SECISBP2L DENND4A HIVEP1 RNF19A JMJD1C TFDP2 DNAJC2 WAC CCNT1 PHF3 MARF1 TMPO FOXP1 KDM6A MED13	8.63e-05	680	182	15	M41089
Coexpression	PEREZ_TP53_TARGETS	TRPM6 PHLDB3 LPAR5 KALRN GGT6 DIDO1 ITGAM GLCCI1 WDR47 ARHGAP6 MINDY3 MOXD1 KRBA1 LLGL1 ZNF398 EGFLAM MTCL1 MCF2L GOLGA8A IL2RB KDM6A	9.72e-05	1201	182	21	M4391
Coexpression	PUJANA_ATM_PCC_NETWORK	ICOSLG FLT1 RIPOR2 GCFC2 ERCC5 CUL9 DIDO1 GRIK1 TFDP2 DNAJC2 PTPRC NFATC3 PHF3 PRDX3 ALPK3 TMPO ZFYVE26 TNKS PAX3 LY9 M6PR PHIP NPAT	1.06e-04	1394	182	23	M9585
Coexpression	ZHENG_FOXP3_TARGETS_IN_T_LYMPHOCYTE_DN	RAPGEF6 WNK1 PTPRC FOXP1	1.38e-04	38	182	4	M1751
Coexpression	GSE13547_CTRL_VS_ANTI_IGM_STIM_ZFX_KO_BCELL_12H_DN	USP28 KIZ TGFBR3 FOXP1 TANC1 QSER1 KAT6B	1.43e-04	162	182	7	M7002
Coexpression	GSE15330_HSC_VS_MEGAKARYOCYTE_ERYTHROID_PROGENITOR_UP	RAPGEF6 USP28 KIZ TGFBR3 POLI FOXP1 TANC1	1.43e-04	162	182	7	M7005
CoexpressionAtlas	DevelopingLowerUrinaryTract_e13.5_bladder neck-urethr mesench_emap-3087_top-relative-expression-ranked_1000	ANK2 EBF3 ZNF521 C11orf87 GRIK1 FOXJ3 DNAJC2 WAC TTLL7 HOXA1 MOXD1 NALCN PTPRO PCDH11X MLF1 INSYN2B LIMCH1 MTCL1 KAT6B FAM135A RNF182 EPHA7	1.32e-06	827	175	22	gudmap_developingLowerUrinaryTract_e13.5_bladder neck-urethr mesench_1000
CoexpressionAtlas	DevelopingGonad_e12.5_ovary_emap-28876_k-means-cluster#5_top-relative-expression-ranked_500	BIRC6 GREB1L BNC1 MBTPS2 INSYN2B KDM6A RNF182	1.04e-05	91	175	7	gudmap_developingGonad_e12.5_ovary_k5_500
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30902_top-relative-expression-ranked_1000	CTTNBP2 KALRN EBF3 FOXJ3 TASOR2 HOXA1 BNC1 ARHGAP6 MOXD1 PHF3 PCDH11X FOXP1 INSYN2B TNKS MTCL1 FAM135A PHIP MED13 PLXNA2 EPHA7	1.16e-05	806	175	20	DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30902_1000
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30902_k-means-cluster#2_top-relative-expression-ranked_1000	KALRN EBF3 FOXJ3 MOXD1 PCDH11X MTCL1 PLXNA2 EPHA7	1.94e-05	138	175	8	DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30902_k2_1000
CoexpressionAtlas	DevelopingGonad_e14.5_ ovary_emap-6699_top-relative-expression-ranked_1000	ZNF385B TEX15 BIRC6 JMJD1C RNF157 TASOR2 WDR47 GREB1L BNC1 ALMS1 MBTPS2 NFATC3 MLF1 ANKRD17 INSYN2B LRRN4 KDM6A RNF182 NPAT	2.33e-05	776	175	19	gudmap_developingGonad_e14.5_ ovary_1000
CoexpressionAtlas	alpha beta T cells, T.8Nve.PP, TCRb+ CD8+ CD44low CD62L high, Peyer's Patch, avg-1	RIPOR2 RAPGEF6 USP28 WNK1 BIRC6 TASOR2 TGFBR3 WDR75 FOXP1 TANC1 LY9 IL2RB	2.37e-05	336	175	12	GSM538413_500
CoexpressionAtlas	dev gonad_e12.5_F_VasAssocMesStromOvary_Sma_k-means-cluster#2_top-relative-expression-ranked_1000	TEX15 TFDP2 MLF1 LRRN4 RNF182	4.61e-05	48	175	5	gudmap_dev gonad_e12.5_F_VasAssocMesStromOvary_Sma_k2_1000
CoexpressionAtlas	DevelopingLowerUrinaryTract_e13.5_bladder mesenchyme_emap-3087_top-relative-expression-ranked_500	FLT1 C11orf87 SPECC1 HOXA1 BNC1 ARHGAP6 PCDH11X TMPO TNKS LIMCH1 LRRN4 PLXNA2 RNF182	4.79e-05	420	175	13	gudmap_developingLowerUrinaryTract_e13.5_bladder mesenchyme_500
CoexpressionAtlas	DevelopingLowerUrinaryTract_e13.5_bladder neck-urethr mesench_emap-3087_k-means-cluster#4_top-relative-expression-ranked_1000	EBF3 C11orf87 GRIK1 WAC MOXD1 PCDH11X MLF1 MTCL1 FAM135A RNF182 EPHA7	5.06e-05	307	175	11	gudmap_developingLowerUrinaryTract_e13.5_bladder neck-urethr mesench_1000_k4
CoexpressionAtlas	DevelopingLowerUrinaryTract_e13.5_bladder neck-urethr mesench_emap-3087_top-relative-expression-ranked_500	ANK2 EBF3 ZNF521 C11orf87 WAC TTLL7 MOXD1 NALCN PCDH11X MLF1 INSYN2B RNF182 EPHA7	5.27e-05	424	175	13	gudmap_developingLowerUrinaryTract_e13.5_bladder neck-urethr mesench_500
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ Genital tubercle M_emap-6706_top-relative-expression-ranked_1000	DENND4A CTTNBP2 EBF3 ZNF521 KBTBD7 TASOR2 BNC1 ARHGAP6 NALCN TMPO FOXP1 INSYN2B PAX3 LIMCH1 KAT6B FAM135A MED13 RNF182 EPHA7	6.37e-05	836	175	19	gudmap_developingLowerUrinaryTract_e14.5_ Genital tubercle M_1000
CoexpressionAtlas	DevelopingLowerUrinaryTract_e13.5_bladder mesenchyme_emap-3087_top-relative-expression-ranked_1000	FLT1 ZNF521 C11orf87 SPECC1 TTLL7 HOXA1 MMRN1 BNC1 ARHGAP6 PCDH11X TMPO FOXP1 TNKS LIMCH1 LRRN4 TACC3 MED13 PLXNA2 RNF182	6.47e-05	837	175	19	gudmap_developingLowerUrinaryTract_e13.5_bladder mesenchyme_1000
CoexpressionAtlas	FacebaseRNAseq_e9.5_Mandibular Arch_top-relative-expression-ranked_2500_k-means-cluster#2	RAPGEF6 HIVEP1 DIDO1 WNK1 JMJD1C WAC LLGL1 ZFYVE9 GTF3C1 ATRIP TMPO ANKRD17 QSER1 FAM135A NPAT	7.06e-05	564	175	15	Facebase_RNAseq_e9.5_Mandibular Arch_2500_K2
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ Genital tubercle F_emap-6706_top-relative-expression-ranked_1000	DENND4A CTTNBP2 ANK2 EBF3 ZNF521 KBTBD7 TASOR2 BNC1 TMPO IGSF9 FOXP1 INSYN2B PAX3 LIMCH1 KAT6B KDM6A FAM135A RNF182 EPHA7	7.92e-05	850	175	19	gudmap_developingLowerUrinaryTract_e14.5_ Genital tubercle F_1000
CoexpressionAtlas	dev gonad_e11.5_F_GonadVasMes_Flk_k-means-cluster#1_top-relative-expression-ranked_1000	HIVEP1 TFDP2 GREB1L PCDH11X MLF1 KAT6B KDM6A PLXNA2 EPHA7	1.04e-04	224	175	9	gudmap_dev gonad_e11.5_F_GonadVasMes_Flk_k1_1000
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30892_top-relative-expression-ranked_1000	CTTNBP2 KALRN EBF3 C11orf87 BIRC6 DNAJC2 HOXA1 MOXD1 PHF3 PCDH11X IGSF9 FOXP1 TNKS MTCL1 FAM135A MED13 PLXNA2 EPHA7	1.25e-04	806	175	18	gudmap_developingLowerUrinaryTract_e14.5_ urethra_1000
CoexpressionAtlas	dev gonad_e11.5_F_ReproVasc_Flk_top-relative-expression-ranked_200	FLT1 STAB2 EBF3 MMRN1 PIEZO2 CD68 LIMCH1 ENG	1.37e-04	182	175	8	gudmap_dev gonad_e11.5_F_ReproVasc_Flk_200
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ urogenital sinus_emap-5517_top-relative-expression-ranked_1000	ANK2 KALRN C11orf87 WNK1 BIRC6 ARHGAP6 NALCN PTPRO PHF3 PCDH11X FOXP1 TNKS KAT6B ENG PHIP MED13 PLXNA2 EPHA7	1.50e-04	818	175	18	gudmap_developingLowerUrinaryTract_e14.5_ urogenital sinus_1000
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ urogenital sinus_emap-6689_top-relative-expression-ranked_500	EBF3 C11orf87 RNF157 NALCN PTPRO PHF3 PCDH11X FAM135A PHIP MED13 RNF182 EPHA7	2.30e-04	427	175	12	DevelopingLowerUrinaryTract_e14.5_ urogenital sinus_emap-6689_500
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30892_k-means-cluster#5_top-relative-expression-ranked_500	KALRN PCDH11X FOXP1 TNKS MED13 PLXNA2 EPHA7	2.41e-04	149	175	7	gudmap_developingLowerUrinaryTract_e14.5_ urethra_500_k5
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30892_k-means-cluster#2_top-relative-expression-ranked_1000	C11orf87 BIRC6 PHF3 PCDH11X FOXP1 TNKS FAM135A MED13 PLXNA2 EPHA7	2.75e-04	312	175	10	gudmap_developingLowerUrinaryTract_e14.5_ urethra_1000_k2
CoexpressionAtlas	gamma delta T cells, Tgd.vg2-.Sp, TCRd+ Vg2- CD44-, Spleen, avg-3	RIPOR2 RAPGEF6 CARMIL2 JADE2 USP28 NFATC3 OSBPL5 FOXP1 TANC1 ENG IL2RB	3.42e-04	382	175	11	GSM476684_500
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ urogenital sinus_emap-5517_k-means-cluster#2_top-relative-expression-ranked_500	KALRN C11orf87 BIRC6 PHF3 PHIP MED13 PLXNA2 EPHA7	3.51e-04	209	175	8	gudmap_developingLowerUrinaryTract_e14.5_ urogenital sinus_500_k2
CoexpressionAtlas	dev gonad_e13.5_F_VascAssocMesenchStromOvary_Sma_k-means-cluster#3_top-relative-expression-ranked_1000	TEX15 TFDP2 LRRN4 RNF182	3.56e-04	41	175	4	gudmap_dev gonad_e13.5_F_VascAssocMesenchStromOvary_Sma_k3_1000
CoexpressionAtlas	DevelopingGonad_e12.5_ovary_emap-28876_top-relative-expression-ranked_1000	DIDO1 GRIK1 BIRC6 JMJD1C RNF157 GREB1L MMRN1 BNC1 MBTPS2 PCDH11X ANKRD17 INSYN2B LRRN4 KDM6A PLXNA2 RNF182 EPHA7	3.65e-04	804	175	17	gudmap_developingGonad_e12.5_ovary_1000
CoexpressionAtlas	dev gonad_e11.5_F_GonMes_Sma_k-means-cluster#1_top-relative-expression-ranked_500	TEX15 TFDP2 MLF1 LRRN4	4.28e-04	43	175	4	gudmap_dev gonad_e11.5_F_GonMes_Sma_k1_500
ToppCell	background-Endothelial_cells\|background / Sample and Cell Type and Tumor Cluster (all cells)	FLT1 RIPOR2 STAB2 KALRN ZNF521 MMRN1 TGFBR3 PIEZO2 TANC1 LIMCH1 ENG	5.99e-10	196	183	11	e6fb0bfab1779ec64a8c35d01519eaafbf62e977
ToppCell	10x5'-GI_small-bowel-Lymphocytic_T_CD4-T_CD4/CD8\|GI_small-bowel / Manually curated celltypes from each tissue	DENND4A BIRC6 JMJD1C TASOR2 NF1 PTPRC KDM6A MED13 TP53BP1	8.91e-08	188	183	9	ab9b725d6e0cdab8e9ddda6dee09e14730e9a578
ToppCell	renal_papilla_nuclei-Adult_normal_reference\|renal_papilla_nuclei / Celltypes from Cells and Nuclei per compartment and clinical group	ANK2 KIZ TFDP2 GREB1L PLEKHG4B TGFBR3 MOXD1 TANC1 ENG	1.07e-07	192	183	9	6c106b91e46eabbe686a52a65a9c94ad9cbe9390
ToppCell	10x_3'_v2v3-Non-neoplastic-Lymphoid-CD4/CD8-CD8_NK_sig-C\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	UBAP2 RNF19A TFDP2 TGFBR3 PTPRC GTF3C1 OSBPL5 IL2RB TP53BP1	1.17e-07	194	183	9	6be74e4ba631b0c46cef2c580553f4c1ed29579e
ToppCell	background-Endothelial_cells\|World / Sample and Cell Type and Tumor Cluster (all cells)	FLT1 RIPOR2 STAB2 CTTNBP2 KALRN MMRN1 TGFBR3 LIMCH1 ENG	1.22e-07	195	183	9	c7d60dabfc7cb310e002cab10003dadfcc34fe33
ToppCell	TCGA-Skin-Metastatic-Melanoma\|TCGA-Skin / Sample_Type by Project: Shred V9	FLT1 DENND4A ITGAM JMJD1C PTPRC ALMS1 NFATC3 KAT6B PHIP	1.39e-07	198	183	9	af4fb9eb2295c7b90624b38ba25619aa15254efa
ToppCell	TCGA-Skin-Metastatic\|TCGA-Skin / Sample_Type by Project: Shred V9	FLT1 DENND4A ITGAM JMJD1C PTPRC ALMS1 NFATC3 KAT6B PHIP	1.39e-07	198	183	9	ad39cce004867f083f8da1954e0cf5a263815184
ToppCell	TCGA-Skin-Metastatic-Melanoma-Skin_Cutaneous_Melanoma\|TCGA-Skin / Sample_Type by Project: Shred V9	FLT1 DENND4A ITGAM JMJD1C PTPRC ALMS1 NFATC3 KAT6B PHIP	1.39e-07	198	183	9	62cbf4b29e8af4983fb47a17f96da62682a5137e
ToppCell	10x5'-bone_marrow-Lymphocytic_T_CD4-T_CD4/CD8\|bone_marrow / Manually curated celltypes from each tissue	DENND4A RAPGEF6 RNF19A JMJD1C PTPRC FOXP1 GOLGA8A KDM6A	2.79e-07	156	183	8	1545169694f686d28648a68b552c2ae606599d66
ToppCell	PBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Lymphocytic-Lymphocytic_ILC-NK_cell-NK_c02-NCAM1\|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k)	EBF3 ZNF521 GLCCI1 MMRN1 TGFBR3 OSBPL5 GOLGA8A IL2RB	3.72e-07	162	183	8	9b1c07f0af657095379380c39d763cab0ad73e74
ToppCell	5'-GW_trimst-2-LymphNode-Endothelial-blood_vessel_EC-Fetal_venous_EC\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	FLT1 EBF3 ZNF521 C11orf87 MMRN1 PCDH11X LIMCH1 ENG	6.40e-07	174	183	8	6b5ff1cc5fe6705f7ea70b5a892dfbf91e32288d
ToppCell	Adult-Immune-natural_killer_cell-D175\|Adult / Lineage, Cell type, age group and donor	RIPOR2 SIRPG TGFBR3 FCRL3 PTPRC OSBPL5 LY9 IL2RB	8.27e-07	180	183	8	fc59e28f39e7d4fb1bcc7205202cf39224b70d7b
ToppCell	human_hepatoblastoma-Tumor_cells\|World / Sample and Cell Type and Tumor Cluster (all cells)	HIVEP1 KIZ WNK1 PHF3 TNKS KDM6A PHIP MED13	1.34e-06	192	183	8	916fbec1c7ab7969bda711886ac88e877e30c280
ToppCell	LPS_only-Endothelial-Endothelial-Vein\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	FLT1 KALRN TNFRSF6B ZNF521 MMRN1 TGFBR3 LIMCH1 ENG	1.34e-06	192	183	8	52acaecd3703166f5ce3b328aff7c82bd142fee4
ToppCell	10x5'-lymph-node_spleen-Lymphocytic_T_CD4-T_CD4/CD8\|lymph-node_spleen / Manually curated celltypes from each tissue	DENND4A RAPGEF6 RNF19A JMJD1C PTPRC FOXP1 GOLGA8A KDM6A	1.34e-06	192	183	8	47646d7e4990be85072987f92bf18d52f8da752e
ToppCell	human_hepatoblastoma\|World / Sample and Cell Type and Tumor Cluster (all cells)	HIVEP1 KIZ WNK1 PHF3 TNKS KDM6A PHIP MED13	1.40e-06	193	183	8	e6a688bc834f845ff64dae1be64f073eec5091a1
ToppCell	Control-Stromal-Myofibroblast\|Stromal / Disease state, Lineage and Cell class	DTNA ARHGAP6 MOXD1 PIEZO2 NALCN TANC1 LIMCH1 PLXNA2	1.40e-06	193	183	8	5896242f713ae5fd1a4ebb63827f15d7279dced2
ToppCell	RA-03._Atrial_Cardiomyocyte\|World / Chamber and Cluster_Paper	ANK2 DTNA USP28 ZNF385B GREB1L MLF1 TANC1 EPHA7	1.45e-06	194	183	8	89812fb164065041357bb37a3c2d87028ec3de4e
ToppCell	Smart-seq2-tissue-resident_(Smart-seq2)-lymphocytic-innate_lymphocytic-mature_NK_T_cell\|tissue-resident_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	USP28 TFDP2 TGFBR3 FCRL3 PTPRC GTF3C1 OSBPL5 IL2RB	1.45e-06	194	183	8	ae5357e2a276473cde1fc8c43acaf9f69da35fd7
ToppCell	Smart-seq2-tissue-resident_(Smart-seq2)-lymphocytic-innate_lymphocytic\|tissue-resident_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	USP28 TFDP2 TGFBR3 FCRL3 PTPRC GTF3C1 OSBPL5 IL2RB	1.45e-06	194	183	8	3a0b8b5d0354c43da57bb951cd8ba878363c3de5
ToppCell	control-Lymphoid-Treg\|Lymphoid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	ERCC5 CARMIL2 RBL2 SIRPG PTPRC NFATC3 PHF3 GOLGA8A	1.51e-06	195	183	8	66959ae839eb60a573da06bdd227090ebb5bb9ed
ToppCell	PBMC-Severe-Lymphocyte-T/NK-Other_T-gd_T\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	RIPOR2 JADE2 RBL2 TGFBR3 FCRL3 PTPRC GTF3C1 IL2RB	1.57e-06	196	183	8	418e8e0a51c5cb60e3b903e7d2d800dc8b9f3d5c
ToppCell	PBMC-Severe-Lymphocyte-T/NK-Other_T-gd_T-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	RIPOR2 JADE2 RBL2 TGFBR3 FCRL3 PTPRC GTF3C1 IL2RB	1.57e-06	196	183	8	581fc8c8d42005aacd7b401a2c9d1fc331fb4af7
ToppCell	PBMC-Severe-Lymphocyte-T/NK-Other_T-gd_T-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	RIPOR2 JADE2 RBL2 TGFBR3 FCRL3 PTPRC GTF3C1 IL2RB	1.57e-06	196	183	8	6beaf0c2799424c59819b286fbb5c1a83d85e4d1
ToppCell	PBMC-Severe-Lymphocyte-T/NK-Other_T-gd_T\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	RIPOR2 JADE2 RBL2 TGFBR3 FCRL3 PTPRC GTF3C1 IL2RB	1.57e-06	196	183	8	c35f2349dfe35baa845f790b9f31673dceac54c0
ToppCell	COVID_vent-Lymphocytic-T_cell\|COVID_vent / Disease condition, Lineage, Cell class and subclass	RIPOR2 JADE2 RBL2 RNF157 PTPRC FOXP1 LY9 GOLGA8A	1.63e-06	197	183	8	ad702e440a74d54cfdcb8bb1c66bd8e0e71ab04e
ToppCell	10x3'2.3-week_17-19-Endothelial-stroma-sinusoidal_EC\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	FLT1 STAB2 CTTNBP2 KALRN ZNF521 PIEZO2 ALPK3 ENG	1.63e-06	197	183	8	4e58bbf3ecb30b4c8199adcc04d2eb134d90de56
ToppCell	Mild\|World / Condition, Lineage, Cell class and cell subclass	ERCC5 KALRN SHFL JADE2 RBL2 TFDP2 ATRIP PHF3	1.63e-06	197	183	8	476b0d0389f9fcd4614f6bb1f494281f467f6730
ToppCell	10x_5'_v1-Non-neoplastic-Lymphoid-CD4/CD8-CD8_NK_sig-F_2\|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	RIPOR2 ITGAM TFDP2 TGFBR3 FCRL3 PTPRC NFATC3 OSBPL5	1.69e-06	198	183	8	88bb764b21ca50e56f6c536a2d61d35afd8c3f36
ToppCell	LPS_IL1RA-Endothelial-Endothelial-Gen_Cap\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	FLT1 ZNF521 ITPRID2 BIRC6 FOXP1 MCF2L FAM135A PCNT	1.82e-06	200	183	8	dccec522ab0d7fff62ad6273b02aa9022dbbb8eb
ToppCell	COVID-19-COVID-19_Severe-Lymphocyte-T/NK-gd_T\|COVID-19_Severe / Disease, condition lineage and cell class	JADE2 RBL2 USP28 TGFBR3 FCRL3 PTPRC GTF3C1 IL2RB	1.82e-06	200	183	8	f72bc3f6606ae77fe1b0a972e35b3ce0727804d9
ToppCell	NS-critical-LOC-Myeloid-Basophil\|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	CTTNBP2 COL16A1 HOXA1 PLEKHG4B ARHGAP6 PCDH11X MTCL1	4.53e-06	160	183	7	8a4746463ca1976f7d6de803496c851249ced797
ToppCell	droplet-Liver-nan-3m-Lymphocytic-NK_cell\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FOXJ3 FICD OSBPL5 POLI TNKS LY9 IL2RB	5.33e-06	164	183	7	950f87d9dacee45c9004a9bf894543de38f72ee5
ToppCell	droplet-Liver-nan-3m-Lymphocytic-NK/T\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FOXJ3 FICD OSBPL5 POLI TNKS LY9 IL2RB	5.33e-06	164	183	7	c33910a6d87580902e9e7bd27afe6ea63b5eff8d
ToppCell	droplet-Liver-nan-3m-Lymphocytic\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FOXJ3 FICD OSBPL5 POLI TNKS LY9 IL2RB	5.33e-06	164	183	7	bf0d3ad9016a0b8011a2385bb92f0a4f5edad1d6
ToppCell	wk_08-11-Mesenchymal-Fibroblast-Alveolar_fibro\|wk_08-11 / Celltypes from embryonic and fetal-stage human lung	JADE2 ZSCAN5A ZNF521 MOXD1 ZACN PIEZO2 PCDH11X	5.78e-06	166	183	7	65dafed953b01a9830b54309af75c7a561e88336
ToppCell	moderate-Myeloid-Mast_cell\|Myeloid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	KRT1 CTTNBP2 ZNF521 TTLL7 PIEZO2 FOXP1 MTCL1	5.78e-06	166	183	7	c3835b424c63bf11a4e2c47635dc3787fc4a637a
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell_of_renal_cortex-lymphatic_endothelial_cell_of_renal_cortex\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	STAB2 KALRN EBF3 MMRN1 BNC1 PIEZO2 PLXNA2	8.16e-06	175	183	7	9a96a946db731ba24c9be34bedebf1f4a1372b9e
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell_of_renal_cortex\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	STAB2 KALRN EBF3 MMRN1 BNC1 PIEZO2 PLXNA2	8.16e-06	175	183	7	2b51406a2c2daa13ab4ed283ede038cd11d9e641
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Endothelial-lymphatic_endothelial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	STAB2 KALRN EBF3 MMRN1 BNC1 PIEZO2 PLXNA2	8.16e-06	175	183	7	54c1f080195ad8392a095e83b56a4b54073d4c0d
ToppCell	facs-Skin-nan-18m-Lymphocytic-nan\|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TRPM6 RIPOR2 CARMIL2 RNF157 PTPRC LY9 IL2RB	8.79e-06	177	183	7	6e45e1a5a894ca2e4ebc5cdb17fdf79e9e188185
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell_of_renal_medulla\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	STAB2 KALRN ZNF521 MMRN1 BNC1 PIEZO2 NALCN	8.79e-06	177	183	7	c8a51e480b978dc0ded85583261f2c892e085be8
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Endothelial-lymphatic_endothelial_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	STAB2 KALRN ZNF521 MMRN1 BNC1 PIEZO2 NALCN	8.79e-06	177	183	7	c274fbdc141855ff4581d437d4997c64cc193278
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell_of_renal_medulla-lymphatic_endothelial_cell_of_renal_medulla\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	STAB2 KALRN ZNF521 MMRN1 BNC1 PIEZO2 NALCN	8.79e-06	177	183	7	f5e6df5cafd003bbfbb3b634ee58d0b1e2be5cc7
ToppCell	facs-Skin-nan-18m-Lymphocytic-T_cell\|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TRPM6 RIPOR2 CARMIL2 RNF157 PTPRC LY9 IL2RB	8.79e-06	177	183	7	17065d37fd41f04f67282bee00365daa185e8355
ToppCell	facs-Skin-nan-18m-Lymphocytic\|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TRPM6 RIPOR2 CARMIL2 RNF157 PTPRC LY9 IL2RB	8.79e-06	177	183	7	9ff3a77c5c62c8a950c46ca22cd7bde425b84c9a
ToppCell	356C-Lymphocytic-NK_cells-NK_cell_C\|356C / Donor, Lineage, Cell class and subclass (all cells)	RIPOR2 LPAR5 USP28 GRIK1 TGFBR3 PTPRC IL2RB	9.12e-06	178	183	7	7203149864cc8d5ae25329fdbf15c6b73c3d3595
ToppCell	droplet-Fat-Gat-18m-Endothelial-nan\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FLT1 RNF157 ZFYVE9 TBC1D22A TANC1 LIMCH1 MCF2L	9.45e-06	179	183	7	08cf9986804a6417a9afb19b50c69a3554f71ec6
ToppCell	TCGA-Colorectal-Primary_Tumor-Colorectal_Adenocarcinoma-Mucinous_Colon_Adenocarcinoma-10\|TCGA-Colorectal / Sample_Type by Project: Shred V9	RIPOR2 COL16A1 EBF3 ZNF521 ITGAM NALCN EGFLAM	9.45e-06	179	183	7	cc079ba015326dccde955c5eafa3e4a2e40de192
ToppCell	ILEUM-non-inflamed-(7)_Lymphatics\|non-inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	STAB2 ANK2 KALRN ZNF521 MMRN1 TGFBR3 PIEZO2	9.45e-06	179	183	7	99777a8931356d1206b8ab22aaa1b1d5a600b809
ToppCell	Children_(3_yrs)-Endothelial-endothelial_cell_of_vein-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	TRPM6 FLT1 KALRN ZNF521 MMRN1 MS4A3 MCF2L	9.80e-06	180	183	7	27e8bbee388e64dd79d70b160b76d45b1f398006
ToppCell	COPD-Lymphoid-T_Regulatory\|World / Disease state, Lineage and Cell class	RAPGEF6 RNF19A RGPD1 GLCCI1 SIRPG FCRL3 IL2RB	9.80e-06	180	183	7	51a12fbad5fa7bb12e6d616a02ff9b5141e2b063
ToppCell	3'_v3-bone_marrow-Mast-Mast_cells\|bone_marrow / Manually curated celltypes from each tissue	TRPM6 KRT1 ZNF521 TEX15 TTLL7 MS4A3 MTCL1	1.02e-05	181	183	7	30ec4635474ee0f0ea1415ec0ba7f008d97e8c1a
ToppCell	10x5'-Liver-Lymphocytic_T_CD4-T_CD4/CD8\|Liver / Manually curated celltypes from each tissue	RAPGEF6 RNF19A JMJD1C PTPRC FOXP1 GOLGA8A KDM6A	1.02e-05	181	183	7	f2315414e714ac86211546a935660c4be6e85f1b
ToppCell	droplet-Kidney-nan-18m-Epithelial-kidney_loop_of_Henle_ascending_limb_epithelial_cell\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TEX15 NALCN KCNJ11 KCNJ16 TANC1 MTCL1 CCDC116	1.09e-05	183	183	7	03c7e69136d5a3b9c5b2c91733e9b1c791f45c49
ToppCell	IPF-Lymphoid-T_Regulatory\|IPF / Disease state, Lineage and Cell class	RIPOR2 RNF19A RGPD1 GLCCI1 SIRPG GOLGA8A IL2RB	1.17e-05	185	183	7	221cbd09d94cc0947d0e3c1aa14716d17cb2068d
ToppCell	COPD-Lymphoid-T_Regulatory\|COPD / Disease state, Lineage and Cell class	RAPGEF6 RNF19A RGPD1 GLCCI1 SIRPG FCRL3 IL2RB	1.17e-05	185	183	7	846403edd4c8f646201d519055198fc38b7ffff9
ToppCell	facs-Limb_Muscle-ForelimbandHindlimb\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	KRT1 DENND4A HIVEP1 WNK1 FOXJ3 JMJD1C CCNT1	1.17e-05	185	183	7	eb7d3c1363d5fedc611f9c1a91ea823de251355e
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Immune-Lymphocytic_T/NK-T_Cell-\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	RIPOR2 RBL2 GLCCI1 RNF157 SIRPG PTPRC FOXP1	1.21e-05	186	183	7	bd3bd022b575d9b0ef90d50a5cb874085a827b77
ToppCell	Smart-seq2-spleen_(Smart-seq2)-lymphocytic-innate_lymphocytic\|spleen_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	COL16A1 ITGAM PGC TGFBR3 GTF3C1 OSBPL5 IL2RB	1.21e-05	186	183	7	fc0b488c201a32d829047b58460297df2818b45d
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Immune-Lymphocytic_T/NK-T_Cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	RIPOR2 RBL2 GLCCI1 RNF157 SIRPG PTPRC FOXP1	1.21e-05	186	183	7	924cc357b4c4ce8e9b05773bdab544f0b65474cc
ToppCell	10x5'-Lung-Mast\|Lung / Manually curated celltypes from each tissue	KRT1 CTTNBP2 ZNF521 SPECC1 TTLL7 TANC1 MTCL1	1.26e-05	187	183	7	f8ac5ca5cbe9c6f3d8c0fffc20fe08ca1aea43c0
ToppCell	10x5'-Lung-Mast-Mast_cells\|Lung / Manually curated celltypes from each tissue	KRT1 CTTNBP2 ZNF521 SPECC1 TTLL7 TANC1 MTCL1	1.26e-05	187	183	7	da275d2c774b3e6a8ed77f777dd0676ecf2ddd2c
ToppCell	Smart-seq2-spleen_(Smart-seq2)-lymphocytic-innate_lymphocytic-mature_NK_T_cell\|spleen_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	COL16A1 ITGAM PGC TGFBR3 GTF3C1 OSBPL5 IL2RB	1.26e-05	187	183	7	6981b856187a2e689260ecb7d0a1193a374ee9b9
ToppCell	systemic_lupus_erythematosus-flare-Hematopoietic\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	RIPOR2 RBL2 TFDP2 SIRPG PIEZO2 FOXP1 PRL	1.30e-05	188	183	7	88b808561ebde997ac8a8bbd1d9bbda49bbb6646
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Diff_MatrixFB\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	COL16A1 ANK2 DTNA ARHGAP6 MOXD1 PIEZO2 LIMCH1	1.35e-05	189	183	7	a153b83314cf52808f685296cff8c95af3f4983d
ToppCell	Control-Lymphoid-NK\|Lymphoid / Disease state, Lineage and Cell class	ITGAM TFDP2 TGFBR3 FCRL3 GTF3C1 OSBPL5 IL2RB	1.39e-05	190	183	7	1584c68b58c7f406d9b0e8451beea3e6f8980c56
ToppCell	facs-MAT-Fat-18m-Endothelial-endothelial_cell\|MAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FLT1 TTLL7 LIMCH1 MCF2L ENG LYPD8 PLXNA2	1.39e-05	190	183	7	9aaa48f3aad813c87a45efdbb67d255c94f6e6a4
ToppCell	facs-MAT-Fat-18m-Endothelial\|MAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FLT1 TTLL7 LIMCH1 MCF2L ENG LYPD8 PLXNA2	1.39e-05	190	183	7	34e56c5e7ea6a8f227dbaefe73cbb8818d18b523
ToppCell	facs-MAT-Fat-18m-Endothelial-nan\|MAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FLT1 TTLL7 LIMCH1 MCF2L ENG LYPD8 PLXNA2	1.39e-05	190	183	7	14cdb660ad3aabcf49572173e7628d8b99dcbe6f
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	COL16A1 ANK2 DTNA ARHGAP6 MOXD1 PIEZO2 LIMCH1	1.44e-05	191	183	7	b13229bb7f3713a392271aaf5dbae3edd1b9fe5a
ToppCell	Adult-Immune-natural_killer_cell\|Adult / Lineage, Cell type, age group and donor	RIPOR2 TGFBR3 FCRL3 PTPRC OSBPL5 LY9 IL2RB	1.44e-05	191	183	7	758ec27e47d7662a5175305e98a1506c6859dbf7
ToppCell	LPS-antiTNF-Endothelial-Endothelial-Vein\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	FLT1 KALRN TNFRSF6B ZNF521 MMRN1 MCF2L ENG	1.49e-05	192	183	7	81baf1c4063469bb0c03a8602b40e387ba7b0dfb
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	COL16A1 ANK2 DTNA ARHGAP6 MOXD1 PIEZO2 LIMCH1	1.49e-05	192	183	7	6f4ef24dab544681304b7f8a9dc073e7edaa4cf5
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	COL16A1 ANK2 DTNA ARHGAP6 MOXD1 PIEZO2 LIMCH1	1.49e-05	192	183	7	dcd924d6eb67d33ee9f5d3e8ab6e1d4283d6b708
ToppCell	LPS-IL1RA-Endothelial-Endothelial-Vein\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	FLT1 KALRN TNFRSF6B ZNF521 MMRN1 MCF2L ENG	1.49e-05	192	183	7	717f3d3bbee4d0f64ba1341ee2b00a407ba1e0f3
ToppCell	LPS-IL1RA-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	COL16A1 ANK2 DTNA ARHGAP6 MOXD1 PIEZO2 LIMCH1	1.49e-05	192	183	7	deeecd26972241846b4cb998edf0c7a87ff0c4df
ToppCell	COPD-Stromal-Myofibroblast\|Stromal / Disease state, Lineage and Cell class	DTNA ARHGAP6 MOXD1 PIEZO2 TANC1 LIMCH1 PLXNA2	1.49e-05	192	183	7	62904f94dfce430456f05066522cbf9bd29f4d7e
ToppCell	Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_SST-Inh_L4-6_SST_MTHFD2P6\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	FLT1 RIPOR2 GRIK1 TGFBR3 ARHGAP6 PCDH11X TANC1	1.54e-05	193	183	7	8b77625bf3c87d39767fb391d1beaca4ab02342b
ToppCell	LPS-IL1RA+antiTNF-Endothelial-Endothelial-Vein\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	FLT1 KALRN TNFRSF6B ZNF521 MMRN1 MCF2L ENG	1.54e-05	193	183	7	7261c1ce30c796b61c6ec58e64a051baa24732ff
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	COL16A1 ANK2 DTNA ARHGAP6 MOXD1 PIEZO2 LIMCH1	1.54e-05	193	183	7	fb28717fadd06c3840636d25409ce80c9254bd34
ToppCell	Mild_COVID-19\|World / Disease group,lineage and cell class （2021.01.30）	KALRN SHFL JADE2 DTNA RBL2 TFDP2 ATRIP	1.54e-05	193	183	7	325b0768827bf8701bfb7f686bb11fd8b1a41a5c
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	COL16A1 TGFBR3 ARHGAP6 MOXD1 PIEZO2 LIMCH1 RNF182	1.59e-05	194	183	7	e93de9428c986b8943fc169258847c650cfab0e5
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	COL16A1 ANK2 DTNA ARHGAP6 MOXD1 PIEZO2 LIMCH1	1.59e-05	194	183	7	89b706af2b25991fc2707eb24f49ba6ff3ae01f7
ToppCell	RA-03._Atrial_Cardiomyocyte\|RA / Chamber and Cluster_Paper	ANK2 DTNA USP28 ZNF385B GREB1L MLF1 TANC1	1.59e-05	194	183	7	c3535f7cc0076653c72db582047cff053c322397
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	COL16A1 ANK2 DTNA ARHGAP6 MOXD1 PIEZO2 LIMCH1	1.59e-05	194	183	7	60622bd2f75bfe4c37f721cb12f03dab33f2f58d
ToppCell	human_hepatoblastoma-NK.T_cells\|human_hepatoblastoma / Sample and Cell Type and Tumor Cluster (all cells)	RIPOR2 GLCCI1 SIRPG FCRL3 PTPRC INSYN2B IL2RB	1.59e-05	194	183	7	997b02a22d7c89a8fd5615bb79a2a8a34fc3fee6
ToppCell	COVID-19-Fibroblasts-Alveolar_FB\|COVID-19 / group, cell type (main and fine annotations)	CTTNBP2 DTNA ARHGAP6 MOXD1 PIEZO2 TANC1 LIMCH1	1.65e-05	195	183	7	603050beeb33c331d4b2e3fa46cae3f3e0e4bdc7
ToppCell	3'_v3-lymph-node_spleen-Lymphocytic_NK-NK_CD16\|lymph-node_spleen / Manually curated celltypes from each tissue	USP28 TFDP2 TGFBR3 FCRL3 GTF3C1 OSBPL5 IL2RB	1.65e-05	195	183	7	e756733cf48768bf40058d6cf9039e52f7563133
ToppCell	COVID-19_Severe-Lymphoid_T/NK-gd_T\|COVID-19_Severe / Disease group, lineage and cell class	RIPOR2 JADE2 RBL2 TGFBR3 PTPRC GTF3C1 IL2RB	1.65e-05	195	183	7	9990440bda7fac5d00ef80444fab07459be625e1
ToppCell	PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Lymphocytic-Lymphocytic_ILC\|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k)	USP28 ITGAM TFDP2 TGFBR3 FCRL3 OSBPL5 IL2RB	1.70e-05	196	183	7	3e78e307c9c991c1aadc85c61d401431cf75eaec
ToppCell	10x5'-Liver-Lymphocytic_NK-NK_CD16\|Liver / Manually curated celltypes from each tissue	ITGAM TFDP2 TGFBR3 FCRL3 GTF3C1 OSBPL5 IL2RB	1.70e-05	196	183	7	e6d4853ccefbcd45a019cee595811f0474dcc036
ToppCell	PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Lymphocytic-Lymphocytic_ILC-NK_cell\|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k)	USP28 ITGAM TFDP2 TGFBR3 FCRL3 OSBPL5 IL2RB	1.70e-05	196	183	7	78b28b263deaa43590b38597186222c6447ad25f
ToppCell	PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Lymphocytic-Lymphocytic_ILC-NK_cell-NK_c01-FCGR3A\|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k)	USP28 ITGAM TFDP2 TGFBR3 FCRL3 OSBPL5 IL2RB	1.70e-05	196	183	7	f0566f2ef96584ed6d9247b149218376fb509915
ToppCell	COVID_non-vent-Lymphocytic\|COVID_non-vent / Disease condition, Lineage, Cell class and subclass	JADE2 RBL2 TGFBR3 FCRL3 FOXP1 GOLGA8A IL2RB	1.76e-05	197	183	7	c672915f8c8c1e948d251f6eaf9f84a5600c1193
ToppCell	COVID_non-vent-Lymphocytic-T_cell-CD8+_Memory_T_cell\|COVID_non-vent / Disease condition, Lineage, Cell class and subclass	JADE2 RBL2 TGFBR3 FCRL3 PTPRC GOLGA8A IL2RB	1.76e-05	197	183	7	836061acd7f0d5de89b16f52ec679bdf09eac9db
ToppCell	IPF-Stromal-Myofibroblast\|Stromal / Disease state, Lineage and Cell class	COL16A1 DTNA ZNF521 MOXD1 PIEZO2 TANC1 LIMCH1	1.76e-05	197	183	7	f304d42fc4936fe20996e07c8dccc698a6e5e5ef
ToppCell	Adult-Mesenchymal\|Adult / Lineage, Cell type, age group and donor	COL16A1 ANK2 ZNF521 TGFBR3 ARHGAP6 MOXD1 PIEZO2	1.82e-05	198	183	7	26e55b409db2a1637c95fae7c54b0abea1ef550c
ToppCell	distal-Hematologic-Natural_Killer-2\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	RIPOR2 USP28 FCRL3 PTPRC GTF3C1 OSBPL5 IL2RB	1.88e-05	199	183	7	928b152f3bade90dfdb15e46aaa0c85063db0026
ToppCell	MS-IIF-Lymphocyte-T/NK-NK_CD56bright\|IIF / Disease, condition lineage and cell class	SHFL ITGAM SPECC1 GLCCI1 MMRN1 GOLGA8A IL2RB	1.88e-05	199	183	7	9eb2b7d4900b118338590db778a47504559e228d
Drug	prazosin hydrochloride; Down 200; 10uM; MCF7; HT_HG-U133A_EA	DTNA ATG13 ITPRID2 NF1 NFATC3 TBC1D22A MLF1 MTCL1 KAT6B TCTN2	3.80e-06	197	179	10	826_DN
Drug	Epirizole [18694-40-1]; Up 200; 17uM; HL60; HT_HG-U133A	ZSCAN5A CUL9 TFDP2 HOXA1 MINDY3 ZFYVE9 PHF3 QSER1 LY9 KAT6B	3.80e-06	197	179	10	1845_UP
Drug	Indapamide [26807-65-8]; Up 200; 10.6uM; MCF7; HT_HG-U133A	ICOSLG DTNA RBL2 CUL9 ITGAM GREB1L LLGL1 TNKS IL2RB KDM6A	3.80e-06	197	179	10	3859_UP
Drug	LY 294002; Up 200; 0.1uM; MCF7; HT_HG-U133A	ICOSLG JADE2 TNFRSF6B GRIK1 SPAG8 RUSC2 GREB1L LIMCH1 MCF2L IL2RB	3.98e-06	198	179	10	5213_UP
Drug	Picotamide monohydrate [80530-63-8]; Down 200; 10.2uM; PC3; HT_HG-U133A	SECISBP2L HIVEP1 ZFYVE16 RNF19A JADE2 TNFRSF6B DIDO1 GTF3C1 LIMCH1 KDM6A	4.16e-06	199	179	10	7140_DN
Drug	Camptothecine (S,+) [7689-03-4]; Down 200; 11.4uM; PC3; HT_HG-U133A	DIDO1 FOXJ3 JMJD1C WAC WDR47 PHF3 MTCL1 KAT6B NPAT	1.32e-05	180	179	9	4541_DN
Drug	Sulindac [38194-50-2]; Up 200; 11.2uM; PC3; HT_HG-U133A	GCFC2 TRIM25 CUL9 HOXA1 ARHGAP6 NFATC3 MARF1 USPL1 KDM6A	2.50e-05	195	179	9	1815_UP
Drug	Chicago sky blue 6B [2610-05-1]; Down 200; 4uM; HL60; HT_HG-U133A	SECISBP2L SHFL RNF19A DTNA TFDP2 TBC1D22A PHF3 TNKS TCTN2	2.50e-05	195	179	9	1330_DN
Drug	Gleevec; Up 200; 10uM; PC3; HG-U133A	STAB2 DTNA RBL2 CUL9 MINDY3 NFATC3 TBC1D22A PRDX3 NPAT	2.60e-05	196	179	9	483_UP
Drug	Cefotaxime sodium salt [64485-93-4]; Down 200; 8.4uM; PC3; HT_HG-U133A	DET1 TNFRSF6B FOXJ3 MOXD1 NFATC3 PHF3 MLF1 KDM6A TCTN2	2.60e-05	196	179	9	5830_DN
Drug	Benzydamine hydrochloride [132-69-4]; Down 200; 11.6uM; PC3; HT_HG-U133A	SECISBP2L TNFRSF6B CUL9 WDR47 ZFYVE9 NFATC3 PHF3 RNFT1 TMPO	2.71e-05	197	179	9	5811_DN
Drug	Medrysone [2668-66-8]; Down 200; 11.6uM; PC3; HT_HG-U133A	GCFC2 UBAP2 RBL2 WNK1 ZFYVE9 NFATC3 TCF25 TMPO KDM6A	2.71e-05	197	179	9	4266_DN
Drug	Hydrastine hydrochloride [5936-28-7]; Up 200; 9.6uM; HL60; HG-U133A	WNK1 NF1 LLGL1 ZFYVE9 PRDX3 LY9 ENG IL2RB HCFC1	2.82e-05	198	179	9	1740_UP
Drug	SB 202190; Down 200; 1uM; PC3; HT_HG-U133A	ICOSLG GCFC2 ATP7B TNFRSF6B CUL9 MOXD1 TBC1D22A ZNF75D QSER1	2.93e-05	199	179	9	6882_DN
Drug	Adiphenine hydrochloride [50-42-0]; Down 200; 11.4uM; MCF7; HT_HG-U133A	SECISBP2L DTNA RBL2 CUL9 WNK1 PHF3 TMPO KDM6A	1.04e-04	183	179	8	1709_DN
Drug	2,4,4'-trichlorobiphenyl	PHLDB3 FLT1 NYAP2 HIVEP1 STAB2 KALRN EBF3 DTNA GGT6 DACT2 PGC TTLL7 NALCN PCDH11X IGSF9 FOXP1 TANC1 QSER1 TACC3 MCF2L IL2RB HCFC1 PHIP CCDC116 PLXNA2	1.18e-04	1411	179	25	ctd:C081766
Drug	Rapamycin; Up 200; 0.1uM; PC3; HT_HG-U133A	NR2E3 TRIM25 RBL2 DIDO1 TFDP2 PHF3 ALPK3 KDM6A	1.20e-04	187	179	8	1242_UP
Drug	Flupentixol dihydrochloride cis-(Z) [2413-38-9]; Down 200; 7.8uM; HL60; HT_HG-U133A	SECISBP2L WNK1 WAC CCNT1 TBC1D22A PHF3 RNFT1 TMPO	1.30e-04	189	179	8	1288_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; HL60; HT_HG-U133A	FLT1 TRIM25 ZSCAN5A ATG13 MBTPS2 RNFT1 KAT6B TCTN2	1.34e-04	190	179	8	2137_DN
Drug	Azathymine, 6 [932-53-6]; Down 200; 31.4uM; HL60; HT_HG-U133A	SECISBP2L GCFC2 DTNA CCNT1 NF1 TMPO KAT6B KDM6A	1.39e-04	191	179	8	2466_DN
Drug	Isotretinoin [4759-48-2]; Down 200; 13.4uM; MCF7; HT_HG-U133A	DTNA CCNT1 ZFYVE9 ALMS1 MBTPS2 SPDEF KDM6A TCTN2	1.39e-04	191	179	8	7438_DN
Drug	Fenbufen [36330-85-5]; Down 200; 15.8uM; MCF7; HT_HG-U133A	DTNA WNK1 ALMS1 RNFT1 ZNF75D LIMCH1 KDM6A TCTN2	1.44e-04	192	179	8	4743_DN
Drug	Atropine sulfate monohydrate [5908-99-6]; Down 200; 5.8uM; HL60; HG-U133A	SECISBP2L ICOSLG DENND4A DTNA ITPRID2 WDR47 TCTN2 NPAT	1.50e-04	193	179	8	1768_DN
Drug	Ricinine [524-40-3]; Down 200; 24.4uM; HL60; HT_HG-U133A	GCFC2 ANK2 TNFRSF6B CCNT1 MINDY3 NF1 MBTPS2 NFATC3	1.50e-04	193	179	8	2505_DN
Drug	PHA-00851261E [724719-49-7]; Down 200; 10uM; PC3; HT_HG-U133A	TRIM25 ZFYVE16 DTNA MINDY3 ZFYVE9 ALMS1 MBTPS2 TBC1D22A	1.50e-04	193	179	8	3773_DN
Drug	forskolin; Up 200; 50uM; HL60; HG-U133A	ATG13 WNK1 CCNT1 PHF3 RNFT1 USPL1 ENG NPAT	1.50e-04	193	179	8	783_UP
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; HL60; HT_HG-U133A	DTNA RUSC2 NF1 ZFYVE9 MBTPS2 PHF3 KAT6B HCFC1	1.50e-04	193	179	8	2721_DN
Drug	(-) -Levobunolol hydrochloride [27912-14-7]; Down 200; 12.2uM; MCF7; HT_HG-U133A	STAB2 SHFL RBL2 WNK1 RUSC2 NF1 ZFYVE9 KAT6B	1.55e-04	194	179	8	4134_DN
Drug	Tiapride hydrochloride [51012-33-0]; Up 200; 11uM; MCF7; HT_HG-U133A	NR2E3 GCFC2 NF1 LLGL1 MLF1 ZNF75D LIMCH1 QSER1	1.61e-04	195	179	8	4686_UP
Drug	ICI182,780; Down 200; 1uM; PC3; HT_HG-U133A	FLT1 STAB2 TRIM25 RNF19A WNK1 MOXD1 NF1 TCTN2	1.61e-04	195	179	8	7539_DN
Drug	Amoxicillin [26787-78-0]; Up 200; 11uM; MCF7; HT_HG-U133A	DTNA TEX15 TTLL7 RUSC2 MINDY3 ZFYVE9 NFATC3 TBC1D22A	1.61e-04	195	179	8	5385_UP
Drug	Phenazopyridine hydrochloride [136-40-3]; Up 200; 16uM; MCF7; HT_HG-U133A	SECISBP2L ATP7B SHFL TNFRSF6B TFDP2 NF1 ZFYVE9 ZFYVE26	1.61e-04	195	179	8	6234_UP
Drug	2,4,5,2',5'-pentachlorobiphenyl	PHLDB3 FLT1 NYAP2 HIVEP1 STAB2 KALRN EBF3 DTNA GGT6 DACT2 PGC TTLL7 NALCN PCDH11X IGSF9 FOXP1 TANC1 QSER1 TACC3 MCF2L IL2RB HCFC1 PHIP CCDC116 PLXNA2	1.63e-04	1441	179	25	ctd:C009828
Drug	Anabasine [494-52-0]; Down 200; 24.6uM; HL60; HT_HG-U133A	ICOSLG SHFL DTNA TFDP2 RUSC2 NF1 NFATC3 MLF1	1.66e-04	196	179	8	2512_DN
Drug	Dipyridamole [58-32-2]; Down 200; 8uM; PC3; HT_HG-U133A	RUSC2 HOXA1 ARHGAP6 NF1 PHF3 LIMCH1 HCFC1 TCTN2	1.66e-04	196	179	8	4656_DN
Drug	Meropenem [96036-03-2]; Down 200; 10.4uM; HL60; HT_HG-U133A	ICOSLG ZFYVE16 TNFRSF6B RUSC2 MINDY3 NF1 ZFYVE9 KDM6A	1.66e-04	196	179	8	6141_DN
Drug	Chlorprothixene hydrochloride [6469-93-8]; Down 200; 11.4uM; PC3; HT_HG-U133A	DENND4A GCFC2 CUL9 HOXA1 ALMS1 PHF3 MLF1 LIMCH1	1.66e-04	196	179	8	6692_DN
Drug	Tocopherol (R,S) [10191-41-0]; Up 200; 9.2uM; MCF7; HT_HG-U133A	ICOSLG DTNA CUL9 PROSER1 WNK1 NF1 PHF3 HCFC1	1.66e-04	196	179	8	3256_UP
Drug	Lymecycline [992-21-2]; Down 200; 6.6uM; HL60; HT_HG-U133A	FLT1 SHFL DTNA RUSC2 PTPRC TMPO TNKS HCFC1	1.66e-04	196	179	8	2953_DN
Drug	Chelidonine monohydrate (+) [476-32-4]; Down 200; 10.8uM; MCF7; HT_HG-U133A	TRIM25 DIDO1 GTF3C1 TBC1D22A PHF3 RNFT1 MCF2L KAT6B	1.66e-04	196	179	8	6236_DN
Drug	Iocetamic acid [16034-77-8]; Up 200; 6.6uM; MCF7; HT_HG-U133A	SHFL DTNA TNFRSF6B SPAG8 PIEZO2 NF1 PHF3 IL2RB	1.72e-04	197	179	8	3361_UP
Drug	Butacaine [149-16-6]; Down 200; 13uM; HL60; HT_HG-U133A	ICOSLG ATP7B DTNA TNFRSF6B ITGAM WNK1 KDM6A HCFC1	1.72e-04	197	179	8	2728_DN
Drug	Amethopterin (R,S) [59-05-2]; Up 200; 8.8uM; MCF7; HT_HG-U133A	NR2E3 SHFL JADE2 TNFRSF6B WNK1 GREB1L LY9 HCFC1	1.72e-04	197	179	8	3214_UP
Drug	Cloxacillin sodium salt [642-78-4]; Down 200; 8.8uM; PC3; HT_HG-U133A	GCFC2 ZFYVE16 TNFRSF6B BNC1 MINDY3 MBTPS2 TMPO ZNF75D	1.72e-04	197	179	8	2126_DN
Drug	Probucol [23288-49-5]; Down 200; 7.8uM; PC3; HT_HG-U133A	DENND4A DTNA TTLL7 HOXA1 ARHGAP6 NF1 PHF3 TCTN2	1.72e-04	197	179	8	4666_DN
Drug	Allantoin [97-59-6]; Up 200; 25.2uM; PC3; HT_HG-U133A	TRIM25 ZFYVE16 PROSER1 TTLL7 MINDY3 NF1 MBTPS2 RNFT1	1.72e-04	197	179	8	1800_UP
Drug	Thiocolchicoside [602-41-5]; Up 200; 7uM; HL60; HG-U133A	SHFL WNK1 JMJD1C TFDP2 ZFYVE9 ZFYVE26 KAT6B HCFC1	1.72e-04	197	179	8	1726_UP
Drug	3-hydroxy-(D/L)-kynurenine; Up 200; 9.2uM; MCF7; HT_HG-U133A_EA	SECISBP2L CCDC91 DTNA FOXJ3 WDR47 MINDY3 NFATC3 RNFT1	1.72e-04	197	179	8	1109_UP
Drug	Mephenytoin [50-12-4]; Down 200; 18.4uM; MCF7; HT_HG-U133A	SECISBP2L TRIM25 ZSCAN5A ITPRID2 TFDP2 RNFT1 KDM6A TCTN2	1.72e-04	197	179	8	6275_DN
Drug	alpha-estradiol; Up 200; 0.01uM; PC3; HT_HG-U133A	TRIM25 WNK1 TFDP2 RUSC2 NF1 NFATC3 PHF3 ALPK3	1.72e-04	197	179	8	1210_UP
Drug	Methyldopate hydrochloride [2508-79-4]; Up 200; 14.6uM; MCF7; HT_HG-U133A	KALRN JADE2 TNFRSF6B TFDP2 MINDY3 NF1 TBC1D22A PHF3	1.72e-04	197	179	8	7360_UP
Drug	chlorpromazine hydrochloride; Up 200; 1uM; MCF7; HT_HG-U133A_EA	RNF19A FOXJ3 NF1 PHF3 ZNF75D USPL1 KDM6A HCFC1	1.72e-04	197	179	8	1055_UP
Drug	Dilazep dihydrochloride [20153-98-4]; Down 200; 6uM; HL60; HT_HG-U133A	SECISBP2L SHFL ATG13 ALMS1 NFATC3 PHF3 LY9 TCTN2	1.78e-04	198	179	8	2333_DN
Drug	Fluorocurarine chloride [22273-09-2]; Down 200; 11.6uM; MCF7; HT_HG-U133A	STAB2 DTNA ATG13 CUL9 ZFYVE9 PHF3 ZNF75D HCFC1	1.78e-04	198	179	8	6083_DN
Drug	Orphenadrine hydrochloride [341-69-5]; Down 200; 13uM; HL60; HT_HG-U133A	SECISBP2L SHFL RNF19A ZSCAN5A ITGAM NFATC3 MLF1 KAT6B	1.78e-04	198	179	8	2356_DN
Drug	Carbinoxamine maleate salt [3505-38-2]; Up 200; 9.8uM; HL60; HT_HG-U133A	KRT1 TEX15 HOXA1 TGFBR3 LLGL1 MBTPS2 ZNF75D QSER1	1.78e-04	198	179	8	2725_UP
Drug	Hydroxytacrine maleate (R,S) [118909-22-1]; Down 200; 12.2uM; MCF7; HT_HG-U133A	SECISBP2L ICOSLG STAB2 RUSC2 CCNT1 NF1 TBC1D22A TCTN2	1.78e-04	198	179	8	3292_DN
Drug	Megestrol acetate [595-33-5]; Down 200; 10.4uM; MCF7; HT_HG-U133A	RNF19A DTNA TNFRSF6B NF1 NFATC3 MLF1 ZNF75D LIMCH1	1.78e-04	198	179	8	6468_DN
Drug	CGP 19984	TRIM25 PRL	1.83e-04	3	179	2	CID006336165
Drug	Clioquinol [130-26-7]; Down 200; 13uM; MCF7; HT_HG-U133A	RNF19A DTNA DIDO1 ITPRID2 NF1 TBC1D22A MCF2L KDM6A	1.85e-04	199	179	8	6461_DN
Drug	Fluocinonide [356-12-7]; Up 200; 8uM; MCF7; HT_HG-U133A	ICOSLG NR2E3 SHFL JADE2 DTNA TNFRSF6B ARSA PRDX3	1.85e-04	199	179	8	3839_UP
Drug	Cyclopentolate hydrochloride [5870-29-1]; Up 200; 12.2uM; MCF7; HT_HG-U133A	SECISBP2L DTNA TEX15 SPAG8 FOXJ3 NF1 ZFYVE9 RNFT1	1.85e-04	199	179	8	6214_UP
Drug	0317956-0000 [391210-11-0]; Up 200; 1uM; PC3; HT_HG-U133A	ICOSLG RIPOR2 DTNA SPAG8 WNK1 NF1 PHF3 TMPO	1.85e-04	199	179	8	4334_UP
Drug	Xylometazoline hydrochloride [1218-35-5]; Down 200; 14.2uM; MCF7; HT_HG-U133A	RNF19A DTNA TFDP2 CCNT1 NFATC3 MLF1 MTCL1 MCF2L	1.85e-04	199	179	8	7020_DN
Drug	Mefenamic acid [61-68-7]; Up 200; 16.6uM; MCF7; HT_HG-U133A	ICOSLG NR2E3 ATG13 NF1 LLGL1 NFATC3 KDM6A PLXNA2	1.85e-04	199	179	8	5534_UP
Drug	Stachydrine hydrochloride; Down 200; 22.2uM; HL60; HG-U133A	SECISBP2L DENND4A RBL2 ITPRID2 JMJD1C HCFC1 TCTN2 NPAT	1.85e-04	199	179	8	1751_DN
Drug	Cefsulodin sodium salt [52152-93-9]; Up 200; 7.2uM; PC3; HT_HG-U133A	RIPOR2 DTNA TEX15 GREB1L ARSA NF1 PHF3 ZNF75D	1.85e-04	199	179	8	4067_UP
Drug	Nomifensine maleate [32795-47-4]; Down 200; 11.2uM; MCF7; HT_HG-U133A	SECISBP2L ATP7B MINDY3 NF1 ALMS1 TBC1D22A PHF3 ZNF75D	1.85e-04	199	179	8	7217_DN
Drug	AH6809; Down 200; 1uM; PC3; HT_HG-U133A	ICOSLG MINDY3 NF1 MBTPS2 TBC1D22A ALPK3 TMPO ZNF75D	1.85e-04	199	179	8	7075_DN
Drug	Flecainide acetate [54143-56-5]; Up 200; 8.4uM; MCF7; HT_HG-U133A	TRIM25 DET1 SHFL RNF19A DTNA TNFRSF6B ARSA TBC1D22A	1.91e-04	200	179	8	3418_UP
Drug	N-Acetyl-L-leucine [1188-21-2]; Up 200; 23uM; MCF7; HT_HG-U133A	KALRN NTSR2 TEX15 TTLL7 MOXD1 PRDX3 PAX3 IL2RB	1.91e-04	200	179	8	5683_UP
Disease	cortical thickness	CCDC91 RIPOR2 NYAP2 CTTNBP2 CUL9 ZNF385B SPECC1 JMJD1C TFDP2 BNC1 LRRIQ1 TBC1D22A CD68 IGSF9 FOXP1 MTCL1 QSER1 TACC3 ARHGAP21 PLXNA2 EPHA7	1.43e-06	1113	167	21	EFO_0004840
Disease	cortical surface area measurement	CCDC91 TRPM6 NYAP2 CTTNBP2 ATG13 RGPD1 CUL9 TFDP2 LRRIQ1 TBC1D22A KCNJ11 KCNJ16 IGSF9 FOXP1 TNKS PAX3 MTCL1 QSER1 TACC3 ARHGAP21 PLXNA2 EPHA7	7.84e-06	1345	167	22	EFO_0010736
Disease	hematocrit	NR2E3 NYAP2 HIVEP1 UBAP2 TRIM25 KALRN JADE2 ANKRD33 LLGL1 ANKRD17 FOXP1 ENG IL2RB CCDC157 ARHGAP21 RNF182 TP53BP1	6.47e-05	1011	167	17	EFO_0004348
Disease	neuroticism measurement, cognitive function measurement	HIVEP1 CTTNBP2 KALRN JADE2 RBL2 ZNF385B BIRC6 JMJD1C SCAP GTF3C1 PTPRO FOXP1	9.81e-05	566	167	12	EFO_0007660, EFO_0008354
Disease	neuroimaging measurement	SECISBP2L CCDC91 CTTNBP2 UBAP2 RGPD1 ZNF521 GLCCI1 JMJD1C NF1 LRRIQ1 WDR75 IGSF9 FOXP1 PAX3 QSER1 TACC3 PLXNA2	1.27e-04	1069	167	17	EFO_0004346
Disease	monocyte count	FLT1 DENND4A NYAP2 HIVEP1 STAB2 KALRN JADE2 ZSCAN5A DIDO1 WNK1 TFDP2 TGFBR3 NF1 PTPRC KCNJ16 SPDEF LY9 ENG NPAT	1.83e-04	1320	167	19	EFO_0005091
Disease	mean reticulocyte volume	RIPOR2 NYAP2 LPAR5 SPECC1 JMJD1C TFDP2 WAC MINDY3 PTPRC GTF3C1 POLI FOXP1 TACC3 ARHGAP21	1.92e-04	799	167	14	EFO_0010701
Disease	X-11423--O-sulfo-L-tyrosine measurement	ARSA PLXNA2	4.71e-04	6	167	2	EFO_0021231
Disease	chronic fatigue syndrome	ARSA EPHA7	4.71e-04	6	167	2	EFO_0004540
Disease	neutropenia, response to metamizole, Drug-induced agranulocytosis	TGFBR3 PTPRO	4.71e-04	6	167	2	EFO_0010971, HP_0012235, MONDO_0001475
Disease	ANEURYSM, INTRACRANIAL BERRY, 1 (disorder)	TGFBR3 ENG	4.71e-04	6	167	2	C1862932
Disease	ARTHROGRYPOSIS, DISTAL, TYPE 2B	PIEZO2 NALCN	4.71e-04	6	167	2	C1834523
Disease	smoking cessation	NYAP2 CTTNBP2 JADE2 BIRC6 JMJD1C ALMS1 TBC1D22A TNKS	5.54e-04	325	167	8	EFO_0004319
Disease	attention deficit hyperactivity disorder, substance abuse, antisocial behaviour measurement	NYAP2 HIVEP1 CTTNBP2 COL16A1 JADE2 USP28 GRIK1 BIRC6 BNC1 KCNU1 ALMS1 FOXP1 PLXNA2	6.69e-04	801	167	13	EFO_0003888, EFO_0007052, MONDO_0002491
Disease	Colorectal Carcinoma	ATP7B ANK2 KALRN ZSCAN5A WNK1 WAC NF1 PCDH11X KDM6A PHIP RNF182 EPHA7	6.88e-04	702	167	12	C0009402
Disease	breast carcinoma	CCDC91 PHLDB3 NYAP2 RNF19A USP28 FAM91A1 GRIK1 JMJD1C TASOR2 KCNU1 WDR75 FOXP1 MTCL1 PHIP PCNT	7.12e-04	1019	167	15	EFO_0000305
Disease	waist circumference, sexual dimorphism	NYAP2 DACT2	8.72e-04	8	167	2	EFO_0004342, EFO_0005951
Disease	2-aminooctanoate measurement	STAMBP ALMS1	8.72e-04	8	167	2	EFO_0800349
Disease	right ventricular systolic volume measurement	RBL2 TGFBR3 MLF1	1.02e-03	35	167	3	EFO_0021815
Disease	Distal arthrogryposis	PIEZO2 NALCN	1.12e-03	9	167	2	cv:C0265213
Disease	longevity	KALRN TEX15 ARSA ATRIP TBC1D22A TCF25 LIMCH1	1.22e-03	284	167	7	EFO_0004300
Disease	neuroimaging measurement, brain volume measurement	CCDC91 CTTNBP2 RGPD1 ZNF521 TFDP2 NF1 ZNF398	1.27e-03	286	167	7	EFO_0004346, EFO_0006930
Disease	cognitive function measurement	DENND4A NYAP2 HIVEP1 KALRN RBL2 ZNF521 BIRC6 GLCCI1 JMJD1C TFDP2 TTLL7 MINDY3 ALMS1 TBC1D22A FOXP1 TNKS ARHGAP21 EPHA7	1.33e-03	1434	167	18	EFO_0008354
Disease	Congenital neurologic anomalies	HOXA1 PAX3	1.39e-03	10	167	2	C0497552
Disease	Cranioschisis	HOXA1 PAX3	1.39e-03	10	167	2	C0265541
Disease	lymphocyte percentage of leukocytes	RIPOR2 NYAP2 HIVEP1 GLCCI1 JMJD1C SIRPG PTPRC GTF3C1 FOXP1 LY9 NPAT	1.49e-03	665	167	11	EFO_0007993
Disease	left ventricular structural measurement	STAB2 ALPK3 KAT6B PHIP	1.59e-03	88	167	4	EFO_0008205
Disease	age at menopause	NYAP2 DIDO1 BIRC6 TASOR2 BNC1 TCF25 LRRN4	1.73e-03	302	167	7	EFO_0004704
Disease	household income	CTTNBP2 KALRN JADE2 TEX15 GLCCI1 JMJD1C FOXP1	1.79e-03	304	167	7	EFO_0009695
Disease	aspartate aminotransferase measurement	RAPGEF6 NYAP2 KALRN TNFRSF6B BIRC6 TTLL7 ARSA NF1 PTPRC PLEKHA3 OSBPL5 TNKS PHIP	1.98e-03	904	167	13	EFO_0004736
Disease	attention deficit hyperactivity disorder, autism spectrum disorder, intelligence	RBL2 KIZ GLCCI1 JMJD1C TFDP2 TTLL7 PTPRO FOXP1	2.01e-03	398	167	8	EFO_0003756, EFO_0003888, EFO_0004337
Disease	N-delta-acetylornithine measurement	STAMBP ALMS1	2.02e-03	12	167	2	EFO_0800067
Disease	alcohol and nicotine codependence	HIVEP1 RGPD1	2.38e-03	13	167	2	EFO_0004776
Disease	testosterone measurement	TRPM6 DENND4A NYAP2 DET1 ANK2 RNF19A JADE2 ZNF385B BIRC6 JMJD1C ARHGAP6 NF1 CD68 FOXP1 PHIP ARHGAP21	2.47e-03	1275	167	16	EFO_0004908
Disease	neutrophil percentage of leukocytes	DENND4A RIPOR2 NYAP2 HIVEP1 KALRN GLCCI1 JMJD1C GTF3C1 ZNF398 FOXP1	2.59e-03	610	167	10	EFO_0007990
Disease	Sarcoma, Spindle Cell	NF1 PAX3	2.77e-03	14	167	2	C0205945
Disease	Sarcoma, Epithelioid	NF1 PAX3	2.77e-03	14	167	2	C0205944
Disease	cholesteryl esters:total lipids ratio, intermediate density lipoprotein measurement	NYAP2 JMJD1C LLGL1 TP53BP1	2.83e-03	103	167	4	EFO_0008595, EFO_0020944
Disease	triglycerides to total lipids in medium LDL percentage	NYAP2 JMJD1C TP53BP1	2.87e-03	50	167	3	EFO_0022334
Disease	cholesteryl esters to total lipids in IDL percentage	NYAP2 JMJD1C TP53BP1	2.87e-03	50	167	3	EFO_0022247
Disease	Alzheimer disease, educational attainment	DENND4A NYAP2 GLCCI1 JMJD1C ARSA TACC3	2.91e-03	247	167	6	EFO_0011015, MONDO_0004975
Disease	triglycerides to total lipids in large LDL percentage	NYAP2 JMJD1C TP53BP1	3.04e-03	51	167	3	EFO_0022331
Disease	polyunsaturated fatty acids to monounsaturated fatty acids ratio	NYAP2 JMJD1C TP53BP1	3.04e-03	51	167	3	EFO_0022302
Disease	liver volume	JMJD1C TP53BP1	3.19e-03	15	167	2	EFO_0600048
Disease	non-dense area measurement, mammographic density measurement	RGPD1 KCNU1	3.19e-03	15	167	2	EFO_0005941, EFO_0006504
Disease	N-acetylmethionine measurement	ALMS1 EPHA7	3.19e-03	15	167	2	EFO_0021427
Disease	Gastro-enteropancreatic neuroendocrine tumor	PTPRC IL2RB	3.19e-03	15	167	2	C2930967
Disease	N-acetylarginine measurement	STAMBP ALMS1	3.63e-03	16	167	2	EFO_0021429
Disease	leptin measurement, type 2 diabetes mellitus	NYAP2 KCNJ11	3.63e-03	16	167	2	EFO_0005000, MONDO_0005148
Disease	triglycerides in large VLDL measurement	NYAP2 JMJD1C TP53BP1	3.96e-03	56	167	3	EFO_0022178
Disease	triglycerides in very large VLDL measurement	NYAP2 JMJD1C TP53BP1	3.96e-03	56	167	3	EFO_0022325
Disease	cholesteryl esters to total lipids in medium HDL percentage	NYAP2 NFATC3 TP53BP1	3.96e-03	56	167	3	EFO_0022251
Disease	Moyamoya Disease	NF1 PCNT	4.10e-03	17	167	2	C0026654
Disease	free cholesterol to total lipids in medium VLDL percentage	NYAP2 JMJD1C TP53BP1	4.16e-03	57	167	3	EFO_0022284
Disease	IGA glomerulonephritis	NYAP2 ITGAM FCRL3	4.37e-03	58	167	3	EFO_0004194
Disease	fibrinogen measurement, factor VII measurement	RAPGEF6 JMJD1C MCF2L	4.37e-03	58	167	3	EFO_0004619, EFO_0004623
Disease	pre-eclampsia (is_marker_for)	FLT1 ITGAM ENG	4.37e-03	58	167	3	DOID:10591 (is_marker_for)
Disease	intelligence, self reported educational attainment	DENND4A JMJD1C ARSA FOXP1	4.47e-03	117	167	4	EFO_0004337, EFO_0004784
Disease	lymphocyte measurement	JMJD1C NFATC3 LY9 CCDC157	4.47e-03	117	167	4	EFO_0803546
Disease	triglycerides in VLDL measurement	NYAP2 JMJD1C TP53BP1	4.59e-03	59	167	3	EFO_0022326
Disease	triglycerides to total lipids in small LDL percentage	NYAP2 JMJD1C TP53BP1	4.59e-03	59	167	3	EFO_0022337
Disease	insulin resistance	NYAP2 ANK2 KCNU1	4.59e-03	59	167	3	EFO_0002614
Disease	Insulin Resistance	ITGAM KCNJ11 CD68	4.81e-03	60	167	3	C0021655
Disease	Insulin Sensitivity	ITGAM KCNJ11 CD68	4.81e-03	60	167	3	C0920563
Disease	cholesterol in chylomicrons and extremely large VLDL measurement	NYAP2 JMJD1C TP53BP1	4.81e-03	60	167	3	EFO_0021898
Disease	total lipids in VLDL measurement	NYAP2 JMJD1C TP53BP1	4.81e-03	60	167	3	EFO_0022314
Disease	cholesterol to total lipids in IDL percentage	NYAP2 JMJD1C TP53BP1	4.81e-03	60	167	3	EFO_0022233
Disease	prostate carcinoma	UBAP2 ANK2 USP28 TASOR2 ARHGAP6 OSBPL5 POLI SPDEF FOXP1 QSER1 ADAMTSL4 PHIP	4.92e-03	891	167	12	EFO_0001663
Disease	cholesterol:total lipids ratio, intermediate density lipoprotein measurement	NYAP2 JMJD1C LLGL1 TP53BP1	5.03e-03	121	167	4	EFO_0008595, EFO_0020943
Disease	triglycerides in small VLDL measurement	NYAP2 JMJD1C TP53BP1	5.04e-03	61	167	3	EFO_0022145
Disease	free cholesterol in very large VLDL measurement	NYAP2 JMJD1C TP53BP1	5.04e-03	61	167	3	EFO_0022274
Disease	Chronic myeloproliferative disorder	ATRIP PCNT	5.11e-03	19	167	2	C1292778
Disease	p-tau:beta-amyloid 1-42 ratio measurement	TBC1D22A EPHA7	5.11e-03	19	167	2	EFO_0007709
Disease	pulmonary non-tuberculous mycobacterial infection	FLT1 SCAP	5.11e-03	19	167	2	MONDO_0018469
Disease	health study participation	JADE2 RBL2 BIRC6 TTLL7 PLXNA2	5.15e-03	195	167	5	EFO_0010130
Disease	alkaline phosphatase measurement	RIPOR2 RBL2 JMJD1C WAC NF1 LLGL1 ATRIP NFATC3 TNKS M6PR ARHGAP21 TP53BP1 TCTN2	5.26e-03	1015	167	13	EFO_0004533
Disease	triglycerides in small HDL measurement	NYAP2 JMJD1C TP53BP1	5.27e-03	62	167	3	EFO_0022158
Disease	phospholipids in large VLDL measurement	NYAP2 JMJD1C TP53BP1	5.27e-03	62	167	3	EFO_0022169
Disease	triglycerides to total lipids in very large HDL percentage	NYAP2 JMJD1C TP53BP1	5.27e-03	62	167	3	EFO_0022339
Disease	total lipids in very large VLDL measurement	NYAP2 JMJD1C TP53BP1	5.27e-03	62	167	3	EFO_0022313
Disease	APOE carrier status, dementia	CCDC91 RIPOR2 C11orf87	5.27e-03	62	167	3	EFO_0007659, MONDO_0001627
Disease	phospholipids in very large VLDL measurement	NYAP2 JMJD1C TP53BP1	5.27e-03	62	167	3	EFO_0022299
Disease	body weight	SECISBP2L CCDC91 HIVEP1 COL16A1 JADE2 KIZ RGPD1 ZNF521 GLCCI1 MOXD1 PHF3 KCNJ16 SPDEF KAT6B M6PR	5.47e-03	1261	167	15	EFO_0004338
Disease	triglycerides to total lipids in IDL percentage	NYAP2 JMJD1C TP53BP1	5.51e-03	63	167	3	EFO_0022329
Disease	triglycerides to total lipids in medium VLDL percentage	NYAP2 JMJD1C TP53BP1	5.51e-03	63	167	3	EFO_0022335
Disease	cholesterol to total lipids in medium VLDL percentage	NYAP2 JMJD1C TP53BP1	5.51e-03	63	167	3	EFO_0022239
Disease	free cholesterol to total lipids in medium LDL percentage	NYAP2 JMJD1C TP53BP1	5.51e-03	63	167	3	EFO_0022283
Disease	phospholipids in chylomicrons and extremely large VLDL measurement	NYAP2 JMJD1C TP53BP1	5.51e-03	63	167	3	EFO_0022292
Disease	puberty onset measurement	DET1 JADE2 BIRC6 JMJD1C	5.64e-03	125	167	4	EFO_0005677

Protein segments in the cluster

Peptide	Gene	Start	Entry
SSSVTVACSGPTHAS	nan	121	Q6ZRM9
EACASESQPHSSALT	AKIRIN1	101	Q9H9L7
HISAASLCSPSRSAF	ARSF	71	P54793
RTHCAATPSSSEDTE	ATG13	336	O75143
SSPRHVTTLSQDSCL	EGFLAM	126	Q63HQ2
ASRLSTSHCSTETPS	CCDC116	511	Q8IYX3
LGTEFNVTSPSNCSH	ADAMTSL4	941	Q6UY14
TESHLATLASSSQSP	BIRC6	3606	Q9NR09
VVSESCSTNPLGNHS	ATP7B	426	P35670
SVHVDCSSASSQPLG	COL16A1	181	Q07092
SIKSRTHSVSADPSC	CARMIL2	1261	Q6F5E8
EACTSPLAKTHTSQA	CFAP36	81	Q96G28
DTPSTTECVSDSLQH	FAM47DP	206	A6NHR8
SHSSSVSAVQSICNA	GRIK1	111	P39086
AFIESCSHRSSSLPT	BNC1	206	Q01954
SQSAPNHCTLAASAS	ALMS1	3021	Q8TCU4
CSTPTSQHGSTATFL	ALPK3	1086	Q96L96
NSSASSSCHLIPTSK	C17orf78	106	Q8N4C9
AASHTGDSSCPTSIT	SPECC1	266	Q5M775
SSNLSLCCSDSHPAS	BTBD11	31	A6QL63
PSVQERSSSCSSHSP	GLCCI1	351	Q86VQ1
HCSSACPSDSVSQTN	AASDH	701	Q4L235
HSSDTSGLSFSQPSC	CCNT1	616	O60563
PSTLSTQSACQNSVH	ANKRD17	2221	O75179
TLHSEVQFPCSASSN	DET1	401	Q7L5Y6
SQITCPTDSGNVTDH	CCDC157	566	Q569K6
THALTSASTLCQVEP	DNAJC2	16	Q99543
NHSIGSTQSTPCSTS	ENG	641	P17813
HFPSSISSQTRQSCI	DENND4A	1516	Q7Z401
SSSPCGLDSIHETSA	NR2E3	211	Q9Y5X4
ATTSLASPFVTTACH	ANKRD33	311	Q7Z3H0
LPAVQSSSFASSTHC	QSER1	516	Q2KHR3
SPARCSRISHTDSSS	MTCL1	196	Q9Y4B5
SSPHTANCDRLSKSS	MSL3P1	276	P0C860
CQQSDHSSPVSSVHS	KAT6B	1591	Q8WYB5
HSSAITCSAHVASVP	LLGL1	391	Q15334
VCSSVGDSHPESQNT	NPAT	706	Q14207
ENSPCVTPVSTATHS	RBL2	411	Q08999
SESFSSSSSLPHCLV	ANK2	2841	Q01484
SCSNSSIILSPAVHL	CD68	276	P34810
DAVAHSAATPTSSCL	PHLDB3	361	Q6NSJ2
SAATPTSSCLFSVHS	PHLDB3	366	Q6NSJ2
SPSCLVQSSSLSNAH	HCFC1	1956	P51610
HSEPIFCTTSISNTC	C22orf46	146	C9J442
SISGSPAESSCQVEH	MINDY3	121	Q9H8M7
STSSCDSHSEASTPQ	KCTD8	356	Q6ZWB6
SQPHLATTPTDSSCS	KRBA1	126	A5PL33
LHCSSSQQLLSSTPS	KRBA1	926	A5PL33
RCLEKSSSSSSQPEH	TMPO	286	P42166
DSHSLSSFTQCPQDS	LPAR5	356	Q9H1C0
SHLLALCSQVPSTST	NTSR2	231	O95665
CHNASTSVSELNATI	MMRN1	931	Q13201
NDCRSPTHLTVSSTN	JMJD1C	1181	Q15652
HTEPSFSSLLSQSSC	FAM91A1	786	Q658Y4
DRAQHAATKCTSPST	FICD	66	Q9BVA6
HVPCSTSRTLGSTDT	KDM6A	576	O15550
HATSTSASRCSKLPS	JADE2	21	Q9NQC1
TAEPCVTSIHSFSSA	KCNJ11	106	Q14654
NHCTESTSAISEIQS	FAM135A	821	Q9P2D6
ISQCVSLAVHPSSIS	PLXNA2	556	O75051
ECAPNVSVSVSTSHT	KRT1	496	P04264
GNNHSSLDLTTTCVS	FOXP1	246	Q9H334
VPSSALCISHSRSSV	KALRN	1701	O60229
KASQTTETHSDTNCP	KCNU1	1061	A8MYU2
APSQLASLSLAHCSS	LRRC29	31	Q8WV35
SDTTADPACHASSSL	ARSA	406	P15289
TVTSSAVCVSPDHDI	KBTBD7	381	Q8WVZ9
SHQEACRSPASETSS	HOXA1	186	P49639
CSVSPTLLAGNHSSE	NYAP2	596	Q9P242
SSSSQAQASALCHSP	PCDH11X	1161	Q9BZA7
IHSSESSCSLPSILN	KIZ	501	Q2M2Z5
SSESSRVSLHCCSNP	OAZ1	46	P54368
SSSQDLQCSRCPTHS	EPHA7	286	Q15375
RQSSASCHSIKPSSS	GREB1L	241	Q9C091
SCHSIKPSSSVSSTV	GREB1L	246	Q9C091
STHSVPNISGATCSA	ITPRID2	866	P28290
SESSSVCSGPSHANR	ITPRID2	1111	P28290
PHSGALSLCSADTSL	PCNT	2246	O95613
VSSHSPLSKSATCEN	LRRIQ1	1271	Q96JM4
CSVTSFSHDSPSVPT	PTPRO	791	Q16827
PTTTVSASCSQRLDH	PAX3	421	P23760
LATAASASTSVPVSC	PROSER1	561	Q86XN7
PHSPSQDELTFTCTS	ICOSLG	146	O75144
LLHSVFSCSSPASSS	ARHGAP6	6	O43182
TSCASVCSDHISPSL	DACT2	141	Q5SW24
DPLSTSQTTSLITHC	GCFC2	571	P16383
CLSSDAIISSPENTH	CCDC91	61	Q7Z6B0
PLSSHQTTECSNSKS	CTTNBP2	1586	Q8WZ74
IPSESSQQSHTSCTY	FOXJ3	316	Q9UPW0
TSSLNCSFGSAHLSP	GGT6	366	Q6P531
PASLSSNHSLTSCFT	IL2RB	346	P14784
CTAVASAASRPDSTH	DIDO1	976	Q9BTC0
PAKATTSCVNAIHTS	MS4A18	376	Q3C1V0
LSATGTSSHSPSECQ	FCRL3	606	Q96P31
TSSHSPSECQEPSSS	FCRL3	611	Q96P31
SQSHDGSSTNCSPII	MARF1	951	Q9Y4F3
TCTASNPVSRSSHQF	LY9	426	Q9HBG7
PNDVQSTSSVLCAHT	MCF2L	261	O15068
SSSSFCIIPSLETHT	MBTPS2	381	O43462
IASECPSHANTSCIS	LYPD8	36	Q6UX82
PSHANTSCISSSASS	LYPD8	41	Q6UX82
SACSTPTHTPQDSLT	DTNA	581	Q9Y4J8
ASIAHCPNSNLSLSS	GDA	296	Q9Y2T3
SNEPSSSSTSRNHSC	CUL9	576	Q8IWT3
SSSTSRNHSCTPDPE	CUL9	581	Q8IWT3
THSSCVSSGVETNPE	ATRIP	451	Q8WXE1
SSVTLPSNCSSTHGI	EBF3	531	Q9H4W6
DHLSSSKQVSSVSPC	POLI	586	Q9UNA4
SSSDTVACHLTHTVP	SCAP	1061	Q12770
VCQSDQSTTLGASHP	LRRN4	361	Q8WUT4
SSEPQHFTTTVTRCS	LIMCH1	656	Q9UPQ0
PASSHCQLTLSSSKT	POM121L1P	141	Q3SYA9
SGNTHSIFCPATSSL	PCARE	1116	A6NGG8
PASSHCQLAHSSSNT	nan	686	A6NNC1
NVSSSSVHDSPLASS	RGPD1	1246	P0DJD0
HSQATESSGSTPESC	OSBPL5	771	Q9H0X9
NIQSLRSCHSSSESP	MS4A3	146	Q96HJ5
KAINSCHTSSLATPE	PRL	81	P01236
VSDPSHCNVLRATSS	RPP30	81	P78346
SSASSSLHARQSPCQ	GOLGA8A	86	A7E2F4
SPAGSSITSCSEEHT	RUSC2	411	Q8N2Y8
DGTQTLTCAHTSAPE	TACC3	286	Q9Y6A5
PQVTHVSSSQSGCSI	RAPGEF6	181	Q8TEU7
TSCSSSSHDNFQSLP	RAPGEF6	1366	Q8TEU7
SLLNHSCSPNTSVSF	SMYD4	536	Q8IYR2
IAQDTCTTTDHSSNP	SPAG8	121	Q99932
HSCSESETQLSQRPS	RNF157	451	Q96PX1
SPTCTNSVSKNETHA	ERCC5	526	P28715
CSDVRHPASLTSSGS	TANC1	1651	Q9C0D5
HSRNPSAASAISFCS	SECISBP2L	846	Q93073
AKLFSTSSSCHAPAV	PRDX3	51	P30048
STCSLTPALAAHFSE	WAC	551	Q9BTA9
ASLVSPSHTSSNCLV	RNF182	116	Q8N6D2
VCPQASLTATHSSTL	HERC2P3	841	Q9BVR0
CSSSCLGVHQVPAST	MED13	301	Q9UHV7
TSQLNTPQDTSCTHI	MED13	1946	Q9UHV7
PQVTFSENLSSTCHT	ITGAM	986	P11215
ARTTPEHTVSFTCES	SIRPG	156	Q9P1W8
APNSHQSSSAASHCS	TFDP2	406	Q14188
CALTSHSTGSPSNST	RIPOR2	441	Q9Y4F9
SSPQGAHAASSCLDT	C11orf87	171	Q6NUJ2
SNPHISSGSTVATCL	SHFL	241	Q9NUL5
EESPCGSQISSEHSV	WDR47	556	O94967
VTCQACHSVSTTIDP	USP51	496	Q70EK9
TGSSEDASTPQCVHT	RNFT1	51	Q5M7Z0
TTSCTALLPSTSQHT	UBAP2	676	Q5T6F2
HALSNEKPVSLTSCS	USPL1	521	Q5W0Q7
LPSTCDSDSSRSEQH	TRPM6	1476	Q9BX84
SLACSPEISHLSVGS	M6PR	176	P20645
AEPLVCGTSSSSSLH	MOXD1	576	Q6UVY6
SQACTSHSRFNPSES	PGC	106	P20142
HSASITSLQFSPLCS	PHIP	266	Q8WWQ0
SPHQCSISVVTQTAS	RNF19A	771	Q9NV58
ISVSPAGDLFCTSHS	WDR75	296	Q8IWA0
HLEDSSACSSEPTQT	PLEKHG4B	696	Q96PX9
TDSEVDSSCSGQPIH	SPDEF	236	O95238
TPCPLTSHVDSDSSS	SPRED3	136	Q2MJR0
LTVSSIQPSDCHTTV	STAMBP	211	O95630
STPSCLSAASSIDNL	TNKS	981	O95271
VEHKTCSPASLSQAS	TRIM25	181	Q14258
ESCNHSNSPSLVTVG	ZNF521	336	Q96K83
SSTSQDHASETPPTC	ZNF398	386	Q8TD17
SSCENPEETTTSATH	KCNJ16	381	Q9NPI9
LSVDPNGHSFCSSSV	MLF1	96	P58340
SLDSHDSISSEPTQC	PIEZO2	1741	Q9H5I5
TPSACVVEREASTHS	ZSCAN5A	271	Q9BUG6
CPTSDAVNHSLSFIS	NF1	1486	P21359
TQRPSSDSGCSHDSV	NFATC3	726	Q12968
PEVSVSSSHSSVSSC	PHF3	211	Q92576
SACASTSHIAETPES	PHF3	1356	Q92576
HTSANCLTNSDGTAS	STAB2	1441	Q8WWQ8
KPSAHASQSFCESSS	TP53BP1	886	Q12888
ASQSFCESSSETPFH	TP53BP1	891	Q12888
LPLSSVHCSVSDQTS	USP28	471	Q96RU2
NSSTGSTCHTTTLPA	ZNF385B	81	Q569K4
CQASSTEGSATHATQ	IGSF9	206	Q9P2J2
VKSVSESHTSCPAES	TBC1D22A	141	Q8WUA7
CSSERSSHSIKEPVS	PLEKHA3	216	Q9HB20
HSSLVQALPSSSSCN	ZACN	276	Q401N2
HPISVSTSEIQTSGC	ZNF75D	286	P51815
TSSTPVSEARNLHCS	TASOR2	546	Q5VWN6
APSSNVASVCIHSTV	WNK1	961	Q9H4A3
TVDSFAASSTVPHCE	TEX15	1361	Q9BXT5
TSSVSEPNVSFVSHC	GTF3C1	556	Q12789
TVAISSSTTLDCHAN	FLT1	671	P17948
TDTPLSLHCNTGSSS	ARHGAP21	1886	Q5T5U3
VSISHNSCTAPDKTL	PTPRC	281	P08575
SLSEDCVASHTTLSQ	ZFYVE26	1071	Q68DK2
LESCSVRPDASVSSH	TCF25	466	Q9BQ70
QTLLVSASHNSSCSA	TCTN2	121	Q96GX1
TPSACVVEREASTHS	ZSCAN5C	271	A6NGD5
ISDPVGTDHCVTSAT	HIVEP1	1586	P15822
VNHLCPTSSDSLASV	ZFYVE9	226	O95405
LPHSNDACSTNSQVS	TTLL7	651	Q6ZT98
SSAAHSIGSTQSTPC	TGFBR3	831	Q03167
LSSVSDTPCVSSTDH	ZFYVE16	166	Q7Z3T8
LNVPGSSSHDTLCTS	TNFRSF6B	181	O95407
STVSNLCHSPAAEST	TMPPE	66	Q6ZT21
TSCLNATSVASHTPG	INSYN2B	256	A6NMK8
LPTTSSSSCDHSKRS	NALCN	681	Q8IZF0